



Europäisches Patentamt  
European Patent Office  
Office européen des brevets

⑪ Publication number:

0 266 576  
A2

⑫

## EUROPEAN PATENT APPLICATION

⑬ Application number: 87114686.6

⑭ Date of filing: 08.10.87

⑮ Int. Cl.4: C07D 215/56 , C07D 401/04 ,  
C07D 471/04 , C07D 471/08 ,  
C07D 519/00 , A61K 31/47 ,  
A61K 31/435 , A61K 31/495 ,  
//(C07D471/04,221:00,221:00),(-  
C07D471/08,221:00,221:00),(C-  
07D487/08,241:00,209:00),(C07-  
D487/08,209:00,209:00),(C07D-  
519/00,487:00,471:00)

⑯ Priority: 08.10.86 US 916752  
25.09.87 US 99231

⑰ Date of publication of application:  
11.05.88 Bulletin 88/19

⑲ Designated Contracting States:  
ES GR

⑳ Applicant: Bristol-Myers Company  
345 Park Avenue  
New York New York 10154(US)

㉑ Inventor: Di Cesare, Pierre  
53, Rue Rene Bazin  
F-77100 Meaux(FR)  
Inventor: Jacquet, Jean-Pierre  
Chemin de St-Thibault  
F-45240 Menestreau-en-Villette(FR)  
Inventor: Essiz, Munir  
4 Mail F.Carcia Lorca  
F-93160 Noisy Le Grand(FR)  
Inventor: Remuzon, Philippe  
25, Rue de Crimée  
F-75019 Paris(FR)  
Inventor: Bouzard, Daniel  
11 Rue Amiat  
F-95130 Franconville(FR)  
Inventor: Weber, Abraham  
4 Avenue Herbillon  
F-94160 Saint-Mande(FR)

㉒ Representative: Kinzebach, Werner, Dr.  
Patentanwälte Reitstötter, Kinzebach &  
Partner Sternwartstrasse 4 Postfach 86 06 49  
D-8000 München 86(DE)

EP 0 266 576 A2

㉓ 1-Tert-alkyl-substituted naphthyridine and quinoline carboxylic acids as antibacterial agents.

㉔ There are disclosed new naphthyridine-and quinoline-carboxylic acids having a 1-tertiary-alkyl substituent, compositions containing them, and their use in treating bacterial infections in warm-blooded animals. Also disclosed are novel amines and intermediates used in the preparation of the naphthyridine-and quinoline-carboxylic acids.

**1-TERTIARY-ALKYL-SUBSTITUTED NAPHTHYRIDINE-AND QUINOLINE-CARBOXYLIC ACID ANTIBACTERIAL AGENTS**


**BACKGROUND OF THE INVENTION**

**FIELD OF THE INVENTION**


5 This invention relates to novel 4-oxo-naphthyridine-and 4-oxo-quinoline-3-carboxylic acids derivatives having anti-bacterial activity, to compositions containing the same, and to novel amines and intermediates used in the preparation of the same.

10 **DESCRIPTION OF THE PRIOR ART**

R. Albrecht, Progress in Drug Research, 21, 9-104(1977), describes the development of numerous structural variants having antibacterial activity which are based on the structure of nalidixic acid (1-ethyl-1,4-dihydro-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid) having the following structural formula:



25 One such variant described by Albrecht is the class of compounds referred to as quinoline derivatives, more particularly, derivatives of 1,4-dihydro-4-oxo-3-quinoline carboxylic acids having the following structural formula:




40 Such quinolones unsubstituted in the benzene nucleus, B, wherein R is H, are described as having only slight antibacterial activity. There are disclosed numerous quinoline derivatives having the above structural formula wherein the benzene nucleus, B, possesses substituents selected from halogen, alkyl, cycloalkyl, unsubstituted and substituted phenyl and pyridyl, piperidinyl and piperazinyl to name but a few, especially when such substituent is in the 7-position. See pages 12-15.

45 Further, there are disclosed numerous quinoline derivatives having the above structural formula wherein the pyridone nucleus, A, possesses various substituents in the 1-position selected from unsubstituted lower alkyl groups or lower alkyl substituted with, for example, halogen and hydroxy-groups, lower alkenyl, alkynyl, and unsubstituted and substituted phenyl. Particularly, it is disclosed that in a comparison of activity of these quinoline derivatives having an alkyl group in the 1-position, the effects achieved with smaller radicals always proved to be best and, further, that as a rule the best activity is obtained with the Ethyl group. See page 25, lines 1-5.

50 Another variant described by Albrecht is the class of compounds referred to as naphthyridine derivatives, i.e 1,8-naphthyridine or more particularly 1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid derivatives, having the following structural formula:

5




10 Among the 1,8-naphthyridine derivatives having the above structural formula, there are disclosed derivatives having piperazinyl and pyrrolidinyl groups in the 7-position and ethyl in the 1-position. See pages 51-56. As regards substituents in the 1-position, it is disclosed that among those same 1-position substituents described above in the quinoline derivatives, maximum activity is achieved with ethyl or propyl groups whereas all smaller or larger alkyl groups or those with additional double bonds or functional groups decrease activity. See page 60, lines 8-19.

15 M. P. Wentland and J. B. Cornett, Annual Reports In Medicinal Chemistry, 20, 145-154 (1985) describe modifications and developments in the area of quinolone antibacterial agents subsequent to the review of Albrecht above, particularly with emphasis on developments in 6-fluoro-7-piperazinylquinolones directed toward increasing antibacterial activity against Gram-positive bacteria and against anaerobes as well as 20 against Gram-negative bacteria in comparison to the activity demonstrated by nalidixic acid. Among the more recent agents disclosed are the agents referred to as norfloxacin (1-ethyl-6-fluoro-1,4-dihydro-7-(1-piperazinyl)-4-oxo-quinoline-3-carboxylic acid) and ciprofloxacin (1-cyclopropyl-6-fluoro-1,4-dihydro-7-(1-piperazinyl)-4-oxo-quinoline-3-carboxylic acid).

25 U.S. Patent 3,590,036 discloses numerous 1-substituted-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acids and derivatives thereof having the following formula, including nalidixic acid mentioned above, wherein the substituent on the 1-position can be aliphatic hydrocarbon radicals having one to ten carbon atoms inclusive such as, for example, alkyl, alkenyl and alkynyl radicals. Illustrative of these radicals are methyl, ethyl, n-propyl, i-propyl, 2-butyl, isoamyl, and the like, when alkyl; and 2-propenyl (allyl), 2-methyl-2-propenyl, 3-but enyl, and the like when alkenyl. The substituents on the pyridine nucleus, that is at the 5-, 30 6-, and 7-positions of the naphthyridine ring system, can be lower-alkyl, halo, and lower-cycloalkylamino.

35




40

U. S. Patent 4,284,629 discloses the preparation of certain 4-pyridone-3-carboxylic acids and derivatives thereof having the following structural formula:

45


50



55 or a salt thereof wherein R<sup>1a</sup> denotes an alkyl, cycloalkyl, aralkyl, aryl or an amino group; R<sup>2a</sup> denotes a hydrogen atom or an alkyl, aralkyl or an aryl group; R<sup>3a</sup> denotes a derivative of a carboxyl-group such as a nitrile or ester group; and up to three of the symbols A, B, D and E denote a nitrogen atom and the remaining of the symbols A, B, D, and E denote an optionally substituted carbon atom. Although the patent

discloses that particularly preferred aliphatic radicals  $R^{1a}$  are ethyl and tert-butyl, there is disclosed among the thirty-five actual examples a single example illustrating tertiary-butyl as the  $R^{1a}$  radical, namely, 1-t-butyl-1,4-dihydro-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid (Example 25). However, no biological activity data is disclosed for this example.

5 U. S. Patents 4,359,578 and 4,352,803 disclose antibacterial compounds having the following structural formula:




wherein X is a halogen atom, especially a fluorine atom,  $R^1$  is an ethyl or vinyl group, and  $R^2$  is a hydrogen atom or a lower alkyl group, and non-toxic salts thereof.


20 U. S. Patent 4,146,719 discloses the compound, 1-ethyl-6-fluoro-1,4-dihydro-7-(1-piperazinyl)-4-oxoquinoline-3-carboxylic acid (norfloxacin) and the hydrates and addition salts thereof.

25 German Offen. DE 3142854 discloses 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-piperazinyl-quinoline-3-carboxylic acids including the specific compound wherein the substituent in the 7-position is unsubstituted piperazinyl (ciprofloxacin) as well as 4-substituted piperazinyl wherein the substituent is methyl, ethyl, or beta-hydroxyethyl.


EP 0,153,163 discloses antibacterial compounds having the following structural formula:



40 wherein X is CH, C-Cl, C-F, C-OH, C-O-alkyl having from one to three carbon atoms, C-NH-alkyl having from one to three carbon atoms or N; Y is H, F, Cl or Br; Z is representative of heterocyclic substituents having the formula




or



50 wherein  $R^3$  is hydrogen, methyl, ethyl, 1- or 2-propyl;  $R^1$  is hydrogen, alkyl having one to six carbon atoms or a cation; and  $R^2$  is alkyl having one to four carbon atoms, vinyl, haloalkyl, or hydroxyalkyl having two to four carbon atoms, or cycloalkyl having three to six carbon atoms. Among the numerous actual examples there are disclosed the preparation of two compounds wherein  $R^2$  is a tertiary alkyl group, namely, 1-methylcyclopropyl (See Examples 61 and 68). However, no data showing biological activity for these compounds is disclosed.


55 U. S. Patent 4,571,396 (corresponding to EP 0,159,174) discloses certain naphthyridine-and quinoline-carboxylic acids having antibacterial activity and having the following structural formula:

5




10 wherein Z is an amine substituent selected from

15




20



25 in which R is hydrogen, alkyl or one to three carbon atoms, hydroxyalkyl of two to three carbon atoms, benzyl or *p*-aminobenzyl; R' is hydrogen or alkanoyl of one to three carbon atoms; X is CH, CF, or N; Y is hydrogen, fluoro, or amino; R<sup>1</sup> is hydrogen, alkyl having from one to six carbon atoms or a cation; and R<sup>2</sup> is alkyl having one to four carbon atoms, vinyl, haloalkyl, or hydroxyalkyl having two to four carbon atoms, or cycloalkyl having three to six carbon atoms, and the pharmaceutically acceptable acid addition or base salts thereof.

30 U. S. Patent 4,556,658 discloses antibacterial compounds having the following structural formula

35




40

45 wherein R<sup>1</sup> and R<sup>2</sup> are identical or different and represent a C<sub>1</sub>-C<sub>4</sub> alkyl radical which is optionally substituted by a hydroxyl, amino, methylamino or dimethylamino group, and R<sup>1</sup> and R<sup>2</sup> together with the nitrogen atom to which they are bonded, furthermore form a 5- or 6-membered heterocyclic ring which can additionally have, as a ring member, the atoms or groups -O-, -S-, -SO-, -SO<sub>2</sub>- or >NR<sup>3</sup>. The patented compounds are said to couple low toxicity with a broad antibacterial spectrum against Gram-positive and Gram-negative bacteria, in particular against Enterobacteriaceae, especially against those which are resistant to various antibiotics such as penicillins, cephalosporins, aminoglycosides, sulfonamides and the like.

50 U. S. Patent 4,578,473 discloses an improved process to produce a compound having the structural formula

55

5




10 wherein A is a substituted amino group  $R^1R^2N-$ ; X is H or F; and  $R^2$  is  $C_1-C_3$  alkyl or  $C_1-C_6$  cycloalkyl.  
 U. S. Patents 4,559,341 and 4,559,342 disclose derivatives of the above-mentioned ciprofloxacin having the structural formula

15

20

25




30

35

40


EP O 166 939 discloses antibacterial 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(3-oxo-1-piperazinyl)-3-quinolinecarboxylic acids having the structural formula



EP O 167 763 discloses antibacterial compounds having the structural formula

45

50




55 wherein  $X^1$  and  $X^2$  are the same or different and represent Cl or F provided that they are not both F at the same time and  $R^1$  and  $R^2$ , together with the nitrogen atom to which they are bound, form a 5- or 6-membered ring which can further include -O-, -S-, -SO-, -SO2-, >N-R3 or -CONR3.

Spanish Patent 8504767 discloses a process to produce compounds having the structural formula

5

10




wherein R<sub>1</sub> is hydrogen or lower alkyl, for example, methyl, ethyl, or isopropyl, and R<sub>2</sub> is methyl or ethyl, by reacting a 3-chloro-4-fluoro-(N-alkyl)aniline with ethoxymethylene-malononitrile, cyclizing the resulting intermediate under Friedel-Crafts-conditions, and reacting the resulting intermediate with an appropriate piperazine.

15 South African Patent Application Publication No. 853954 discloses antibacterial compounds having the structural formula

20

25

30




U. S. Patent 4,563,448 discloses a method of combating plant-pathogenic bacteria using a cyclopropyl-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid derivative of the formula

35

40

45




50 Great Britain Patent Application Publication 2 160 519 A discloses quinolone compounds having antibacterial activity having the structural formula

55

5

10




wherein R<sub>1</sub> is H or alkyl.

EP O 132 845 discloses antibacterial 1,8-naphthyridine derivatives of the formula

15

20

25




wherein R<sub>1</sub>, R<sub>2</sub> and R<sub>3</sub> are the same or different and can be hydrogen or lower alkyl having 1 to 5 carbon atoms.

EP O 134 165 discloses antibacterial 7-(pyrrol-1-yl) derivatives of 1-ethyl-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid and 1-ethyl-1,4-dihydro-4-oxo-(1,8-naphthyridine)-3-carboxylic acid of the formula

35

40




wherein X is a carbon atom or nitrogen atom and R is hydrogen or fluoro.

U. S. Patent 4,341,784 discloses antibacterial 7-(3-amino-1-pyrrolidinyl)-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acids of the formula

50

55




Although the recently developed compounds exhibit improvements in antibacterial activity, such as a broader activity spectrum, increased potency, improved absorbability, increased duration of action and improved stability, in comparison with previous compounds, there remains a need for compounds having an advantageous combination of these and other desirable properties.

5 These and other advantages as will be apparent to those skilled in the art to which this invention pertains are achieved by this invention which is described as follows.


SUMMARY OF THE INVENTION

10 This invention in a first aspect is a generic chemical compound representing one of the group of compounds consisting of naphthyridine-and quinoline-carboxylic acids and having the formula



in which R<sup>1</sup> is a unsubstituted or substituted tertiary-alkyl group wherein the t-alkyl group may contain 1-3 halo, e.g. fluoro, groups, X is a halogen or trihalomethyl group, Y is a C or a N atom which provides a quinoline or a naphthyridine ring system, respectively, and Z is a N-heterocyclic ring selected from the group of piperazinyl, piperidinyl, 3-amino-1-pyrrolidinyl, 3-aminoalkyl-1-pyrrolidinyl, 2-aminoalkyl-morpholin-4-yl, 2-aminoalkyl-thiomorpholin-4-yl, and diazabicycloalkyl groups containing 7-9 atoms in the diazabicycloalkyl ring system.

35 In another aspect, this invention is an intermediate for the preparation of compounds of Formula I having the generic formula



wherein R<sup>1</sup>, and X and Y are as defined above, X' may be the same as X above or an alkyl-, aryl- or aralkyl-sulfonyl and M is H or alkyl or a salt-forming metal cation or ammonium ion.


50 In yet another aspect, this invention is an amine compound, Z-H, useful in preparing compounds of Formula I.

55

DETAILED DESCRIPTION OF THE INVENTION

In one aspect, this invention is a compound having the formula

5




(Formula I)

10


wherein:

15 R<sup>1</sup> is a unsubstituted or substituted tertiary alkyl group selected from -C(CH<sub>3</sub>)<sub>3</sub>, -C(CH<sub>3</sub>)<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, -C(C<sub>6</sub>H<sub>5</sub>)-(CH<sub>3</sub>)<sub>2</sub>,

20




25



-C(CH<sub>3</sub>)=CH<sub>2</sub>, and

30




35

wherein R is H or CH<sub>3</sub> and wherein the t-alkyl group may contain 1-3 halo, e.g. fluoro groups; X is a member of the group of halogen groups selected from F, Cl and Br and trihaloalkyl groups selected from CF<sub>3</sub> and CCl<sub>3</sub>;

40 Y is selected from CH, CF, CCl, CBr, and N; and  
Z is selected from


45

50




55

5



10



15

wherein W is NR<sup>2</sup>, S or O.


20



25




30




40

45




wherein R<sup>2</sup> is independently selected from H, unsubstituted and substituted alkyl having 1 to 6 carbon atoms wherein the substituent is independently selected from 1-3 hydroxy, fluoro, chloro, amino, alkylamino, trifluoroacetyl amino and phenyl groups; cycloalkyl having 3 to 6 carbon atoms; and cycloalkenyl having 3 to 6 carbon atoms; and wherein A, B, C, and D are independently selected from H; unsubstituted and substituted lower alkyl having 1 to 4 carbon atoms wherein the substituent is independently selected from 1-3 hydroxy, fluoro, chloro, amino, alkylamino, trifluoroacetyl amino, and phenyl groups; amino; hydroxy; fluoro; chloro; and phenyl groups; and wherein n, when present, is selected from the integers 0, 1, 2, and 3; provided that when R<sup>1</sup> is

55



then Z is not

5



and pharmaceutically acceptable acid addition and base salts thereof.

In those embodiments above containing the  $R^2N$ -moiety wherein each of the  $R^2$  groups is other than H, then  $R^2$  is independently selected from  $CH_3$  and  $C_2H_5$ .


10 It is to be understood that the formulas herein representing the various compounds according to the invention are intended to embrace all optical isomers within the scope of the given formulas unless otherwise indicated.

15 In another aspect, as is mentioned above, this invention is a pharmaceutical composition comprising an antibacterially effective amount of a compound of Formula I above.

20 In still another aspect, this invention is a method of combatting bacterial infection in warm-blooded animals comprising administering to said animals an antibacterially effective amount of a compound of Formula I or of a pharmaceutical composition thereof.

25 In yet another aspect, this invention is a compound having the formula


20




(Formula II)

25

30 wherein:  $R^1$  is a tertiary alkyl group selected from  $-C(CH_3)_3$ ,  $-C(CH_3)_2CH_2CH_3$ ,  $-C(C_6H_5)(CH_3)_2$ ,




35



40

$-C(CH_3)=CH_2$ , and

45



wherein R is H or  $CH_3$ ;

50 X is a member of the group of halogen groups selected from F, Cl, and Br and trihaloalkyl groups selected from  $CF_3$  and  $CCl_3$ ;

X' may be the same as X or an alkyl-, aryl- or aralkylsulfonyl;



Y is selected from CH, CF,  $CCl$ ,  $CBr$  and N; and

M is selected from H,  $Cr-C_4$  alkyl and alkali and alkaline earth metal ions, and ammonium ions.

55 In still another aspect, this invention is a compound represented by the formula

Z-H (Formula III)


wherein ZH is selected from






and the free amine hydrolysis product thereof, and




Preferred compounds of Formula I above according to this invention are those wherein  
20 R<sup>1</sup> is unsubstituted or substituted -C(CH<sub>3</sub>)<sub>3</sub>, -C(CH<sub>3</sub>)<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>,



25 and -C(CH<sub>3</sub>) = CH<sub>2</sub>;  
X is F;  
Y is selected from CH, CF and N; and  
Z is selected from



45 wherein R<sup>2</sup> is independently selected from H, CH<sub>3</sub>, -C<sub>2</sub>H<sub>5</sub> and -C(CH<sub>3</sub>)<sub>3</sub> and




; A, B, C, and D are independently selected from H, CH<sub>3</sub> and C<sub>2</sub>H<sub>5</sub>; and n is selected from 0, 1, and 2.

More preferred compounds of Formula I above according to this invention are those wherein  
R<sup>1</sup> is -C(CH<sub>3</sub>)<sub>3</sub>, -C(CH<sub>2</sub>F)(CH<sub>3</sub>)<sub>2</sub>, -C(CH<sub>2</sub>F)<sub>2</sub>CH<sub>3</sub>, or -C(CF<sub>3</sub>CH<sub>3</sub>)<sub>2</sub>;



55 X is F;  
Y is selected from CH and N; and  
Z is selected from

5:





10

15



Especially preferred compounds of Formula I according to this invention are those wherein  
 R<sup>1</sup> is -C(CH<sub>3</sub>)<sub>3</sub>;  
 X is F;  
 20 Y is CH; and  
 Z is selected from

25



30

Further especially preferred compounds of Formula I according to this invention are those wherein  
 R<sup>1</sup> is -C(CH<sub>3</sub>)<sub>3</sub>;  
 X is F;  
 Y is N; and  
 Z is selected from

35

40

45

R<sup>2</sup> = H or CH<sub>3</sub>

Most especially preferred are the compound of Formula I wherein R<sup>1</sup> is -C(CH<sub>3</sub>)<sub>3</sub>, X is F, Y is N and Z is selected from

50

55


5



10



15




20 By the expressions "cis-isomer" and "trans-isomer" above is meant that the methyl and amino groups are on the same side of the plane of the pyrrolidine ring system or are on opposite sides of the plane of the pyrrolidine ring system, respectively. It will be apparent to those skilled in the art that here there are present 2 asymmetric carbon atoms and, thus, there are two isomers when the methyl and amino groups are cis and two isomers when they are trans.

25 The compounds having formulas I, II, and III may contain an asymmetric carbon atom. As is mentioned above, the formulas I, II and III herein representing the various compounds of the invention are intended to embrace all optical isomers, as well as racemic mixtures thereof, of the compounds within the scope of the given formula.

30 The compounds of this invention may be readily prepared by reacting a compound having the formula

30



(Formula II)

40

wherein R<sup>1</sup>, X, X', Y, and M are as defined above, with an amine,



45

for example, an amine corresponding to the formula Z-H (Formula III)

wherein Z is also as defined above.


50 Although X' in Formula II above may be selected from the same substituents, namely, F, Cl and Br and CF<sub>3</sub> and CCl<sub>3</sub>, which define "X", X' also may be an organic leaving group other than CF<sub>3</sub> and CCl<sub>3</sub>. More preferably, X' may be selected from F and Cl and an organic leaving group such as alkylsulfonyl (for example methanesulfonyl), arylsulfonyl (for example phenylsulfonyl), and aralkylsulfonyl (for example p-toluenesulfonyl).

55 The intermediates of Formula II, wherein R<sup>1</sup> is a tertiary alkyl group as defined above, are novel but may be prepared from known starting materials by standard, or conventional, procedures or by variations thereof. Representative of such procedures are those disclosed in U.S. Patent 4,571,398 and others of the references disclosed in the Description of the Prior Art above.

Certain of the amine starting materials represented by the formula Z-H (Formula III) are novel and may be prepared as described below.

The following reaction sequence illustrates a typical preparation of the compounds of formulas I and also II. In the reaction sequence, R = Et or PhCH<sub>2</sub>, X = X' = F or Cl, and Y = CH, CF or N. According to this method polyhalogenated aromatic acid (1) is converted with sulfonyl chloride to acid chloride (2) which acylates malonate diester in the presence of magnesium ethylate to give the arylmalonate (3).

6 Partial hydrolysis and decarboxylation of (3) in aqueous medium using catalytic amounts of p-toluenesulfonic acid give (4) which is treated with triethyl orthoformate and acetic anhydride to give (5). Reaction of (5) with t-butylamine in ethyl alcohol leads to an isomeric mixture of (6) which is cyclised to (7) with a slight excess of sodium hydride in dioxane. Compound (10) may be obtained from (7) by two ways: (a) Ester (7) is first hydrolyzed under basic condition to lead to carboxylic acid (8) which reacts with the appropriate 10 amine to give (10); and (b) Ester (7) can be converted to (9) with the appropriate amine and the ester (9) hydrolyzed under basic condition to (10).



35 Preferred species of the compounds of this invention include the following:  
 1-(1,1-dimethylethyl)-1,4-dihydro-6-fluoro-7-piperazinyl-4-oxo-3-quinolinecarboxylic acid, methane sulfonate.  
 7-[4-(cyclopenten-3-yl)-1-piperazinyl]-1-(1,1-dimethylethyl)-1,4-dihydro-6-fluoro-4-oxo-3-quinolinecarboxylic acid, hydrochloride.  
 7-(8-methyl-3,8-diazabicyclo[3.2.1]octan-3-yl)-1-(1,1-dimethylethyl)-1,4-dihydro-6-fluoro-4-oxo-3-40-quinolinecarboxylic acid, hydrochloride.  
 7-[(3-phenyl)-1-piperazinyl]-1-(1,1-dimethylethyl)-1,4-dihydro-6-fluoro-4-oxo-3-quinolinecarboxylic acid, methanesulfonate.  
 1-(1,1-dimethylethyl)-1,4-dihydro-6-fluoro-7-(4-methylpiperazinyl)-4-oxo-3-quinolinecarboxylic acid, hydrochloride.  
 45 7-(2,5-diazabicyclo[2.2.2]octan-2-yl)-1-(1,1-dimethylethyl)-1,4-dihydro-6-fluoro-4-oxo-3-quinolinecarboxylic acid.  
 7-(1S,4S-2,5-diazabicyclo[2.2.1]heptan-2-yl)-1-(1,1-dimethylethyl)-1,4-dihydro-6-fluoro-4-oxo-3-quinolinecarboxylic acid.  
 50 7-(3-(aminomethyl)-1-pyrrolidinyl)-1-(1,1-dimethylethyl)-1,4-dihydro-6-fluoro-4-oxo-3-quinolinecarboxylic acid.  
 7-(3-(ethylamino)methyl-1-pyrrolidinyl)-1-(1,1-dimethyl ethyl)-1,4-dihydro-6-fluoro-4-oxo-3-quinolinecarboxylic acid.  
 7-(3-methyl-1-piperazinyl)-1-(1,1-dimethylethyl)-1,4-dihydro-6-fluoro-4-oxo-3-quinolinecarboxylic acid.  
 7-(3,5-dimethyl)-1-piperazinyl)-1-(1,1-dimethylethyl)-1,4-dihydro-6-fluoro-4-oxo-3-quinolinecarboxylic acid.  
 55 7-(4-(dimethylamino)-1-piperazinyl)-1-(1,1-dimethylethyl)-1,4-dihydro-6-fluoro-4-oxo-3-quinolinecarboxylic acid.  
 7-(4-(1,1-dimethylethyl)-1-piperazinyl)-1-(1,1-dimethyl ethyl)-1,4-dihydro-6-fluoro-4-oxo-3-quinolinecarboxylic acid.  
 7-piperazinyl-1-(1,1-dimethylethyl)-1,4-dihydro-6,8-difluoro-4-oxo-3-quinolinecarboxylic acid.

7-(3-(ethylamino)methyl-1-pyrrolidinyl)-1-(1,1-dimethyl ethyl)-1,4-dihydro-6,8-difluoro-4-oxo-3-quinolinecarboxylic acid.

7-(3-amino-1-pyrrolidinyl)-1-(1,1-dimethylethyl)-1,4-dihydro-6-fluoro-4-oxo-3-quinolinecarboxylic acid, hydrochloride

5 7-piperazinyl-1-(1,1-dimethylethyl)-1,4-dihydro-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid.

7-(3-methyl-1-piperazinyl)-1-(1,1-dimethylethyl)-1,4-dihydro-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid.

7-(1S,4S-2,5-diazabicyclo[2.2.1]heptan-2-yl)-1-(1,1-dimethylethyl)-1,4-dihydro-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid.

10 7-(2,5-diazabicyclo[2.2.2]octan-2-yl)-1-(1,1-dimethylethyl)-1,4-dihydro-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid.

7-(4-(cyclopenten-3-yl)-1-piperazinyl)-1-(1,1-dimethylethyl)-1,4-dihydro-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid.

15 7-(3-(aminomethyl)-1-pyrrolidinyl)-1-(1,1-dimethylethyl)-1,4-dihydro-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid.

7-(3-(ethylamino)methyl)-1-pyrrolidinyl)-1-(1,1-dimethyl ethyl)-1,4-dihydro-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid.

20 7-(3-methyl-1-piperazinyl)-1-(1,1-dimethylethyl)-1,4-dihydro-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid.

7-(3-phenyl-1-piperazinyl)-1-(1,1-dimethylethyl)-1,4-dihydro-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid, methanesulfonate.

25 7-(1R,4R-2,5-diazabicyclo[2.2.1]heptan-2-yl)-1-(1,1-dimethylethyl)-1,4-dihydro-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid.

7-(8-methyl-3,8-diazabicyclo[3.2.1]octan-3-yl)-1-(1,1-dimethylethyl)-1,4-dihydro-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid, methanesulfonate salt.

30 7-(3,8-diazabicyclo[3.2.1]octan-3-yl)-1-(1,1-dimethylethyl)-1,4-dihydro-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid, methanesulfonate.

7-(2-aminomethyl-morpholin-4-yl)-1-(1,1-dimethylethyl)-1,4-dihydro-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid.

35 7-(3-amino-1-pyrrolidinyl)-1-(1,1-dimethylethyl)-1,4-dihydro-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid.

7-[(S)-3-amino-1-pyrrolidinyl]-1-(1,1-dimethylethyl)-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid.

40 7-(*trans*-3-amino-4-methyl-pyrrolidin-1-yl)-1-(1,1-dimethylethyl)-1,4-dihydro-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid.

7-(*cis*-3-amino-4-methyl-pyrrolidin-1-yl)-1-(1,1-dimethylethyl)-1,4-dihydro-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid.

The compounds of Formula I according to this invention may be provided as pharmaceutically acceptable acid addition and base salts wherein the anion or cation, respectively, does not contribute significantly to the toxicity of the salt and which salts are compatible with the standard and conventional pharmaceutically acceptable carriers and other conventional adjuvants and excipients customarily employed in producing pharmaceutical compositions adapted for oral or parenteral administration. The acid addition salts are formed by conventional techniques involving reaction of compounds of Formula I with mineral acids such as, for example, hydrochloric acid, hydrobromic acid, phosphoric acid, and sulfuric acid, and with organic carboxylic and sulfonic acids such as, for example, acetic acid, citric acid, maleic acid, succinic acid, benzoic acid, tartaric acid, ascorbic acid, methanesulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic acid, p-toluenesulfonic acid, and the like.

Pharmaceutically acceptable base salts are formed by conventional techniques involving reaction of the compounds of Formula I with alkali (Na, K) and alkaline earth (Ca, Ba, Zn, Mn) metal bases, more preferably with alkali metal bases such as, for example, dilute solutions of sodium hydroxide, and potassium carbonate. Also, pharmaceutically acceptable base salts are formed by conventional techniques involving reaction with amines such as, for example, triethylamine, dibenzylamine, triethanolamine, ethanolamine, N,N'-dibenzylethylenediamine, procaine and equivalent amines.

The pharmaceutical compositions of this invention may be prepared by combining the compounds of Formula I of this invention with a solid or liquid pharmaceutically acceptable carrier and, optionally, with pharmaceutically acceptable adjuvants and excipients employing standard and conventional techniques. Solid form compositions include powders, tablets, dispersible granules, capsules, cachets and suppositories. A solid carrier can be at least one substance which may also function as a diluent, flavoring agent, solubilizer, lubricant, suspending agent, binder, tablet disintegrating agent, and encapsulating agent. Inert solid carriers include magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, cellulosic materials, low melting wax, cocoa butter, and the like. Liquid form compositions include solutions, suspensions and emulsions. For example, there may be provided solutions of the compounds of this invention dissolved in water and water-propylene glycol and water-polyethylene glycol systems, optionally containing suitable conventional coloring agents, flavoring agents, stabilizers and thickening agents.

Preferably, the pharmaceutical composition is provided employing conventional techniques in unit dosage form containing appropriate amounts of the active component, that is, the compound of Formula I according to this invention.

The quantity of active component, that is the compound of Formula I according to this invention, in the pharmaceutical composition and unit dosage form thereof may be varied or adjusted widely depending upon the particular application, the potency of the particular compound, and the desired concentration. Generally, the quantity of active component will range between 0.5% to about 90% by weight of the composition.

In therapeutic use for treating, or combatting bacterial infections in warm-blooded animals, the compounds or pharmaceutical compositions thereof will be administered at a dosage to obtain and maintain a concentration that is, an amount, or blood-level of active component in the animal undergoing treatment which will be antibacterially effective. Generally, such antibacterially effective amount of dosage of active component will be in the range of about 0.1 to about 15, more preferably about 1.5 to about 10, still more preferably about 3 to about 7 mg/kg of body weight/day. It is to be understood that the dosages may vary depending upon the requirements of the patient, the severity of the bacterial infection being treated, and the particular compound being used. Also, it is to be understood that the initial dosage administered may be increased beyond the above upper level in order to rapidly achieve the desired blood-level or the initial dosage may be smaller than the optimum and the daily dosage may be progressively increased during the course of treatment depending on the particular situation.

The compounds of formula I according to this invention are advantageously administered parenterally, i.e. by injection, for example, by intravenous injection or by other parenteral routes of administration. Pharmaceutical compositions for parenteral administration will generally contain a pharmaceutically acceptable amount of the compound according to formula I as a soluble salt (acid addition salt or base salt) dissolved in a pharmaceutically acceptable liquid carrier such as, for example, water-for-injection and a buffer to provide a suitably buffered isotonic solution, for example, having a pH of about 3.5-6. Suitable buffering agents include, for example, trisodium orthophosphate, sodium bicarbonate, sodium-citrate, N-methylglucamine, L(+)-lysine and L(+)-arginine to name but a few representative buffering agents. The compound according to formula I generally will be dissolved in the carrier in an amount sufficient to provide a pharmaceutically acceptable injectable concentration in the range of about 1 mg/ml to about 400 mg/ml of solution. The resulting liquid pharmaceutical composition will be administered so as to obtain the above-mentioned antibacterially effective amount of dosage in the range of about 0.1 to about 15, more preferably about 1.5 to about 10, still more preferably about 3 to about 7 mg/kg of body weight/day.

The following examples are presented to illustrate but a few representative embodiments of the invention and are not to be construed as limiting in scope. All parts and percentages are by weight and all temperatures are in degrees Celsius unless otherwise indicated.

Examples 1 to 44 describe different methods used to prepare representative compounds according to the invention.

Examples A to H describe preparations of sofar unknown amines.

Examples I to XII describe preparations of quinolone and naphthyridone intermediates bearing the t-butyl (1,1-dimethylethyl) group.

## 55 PREPARATION OF QUINOLONE AND NAPHTHYRIDONE ANTIBACTERIAL COMPOUNDS

EXAMPLE 11-(1,1-DIMETHYLETHYL)-1,4-DIHYDRO-6-FLUORO-7-PIPERAZINYL-4-OXO-3-QUINOLINECARBOXYLIC ACID, METHANESULFONATE

5

Method 1 :

A suspension of 17.7 g (59.4 mmoles) 1-(1,1-dimethylethyl)-1,4-dihydro-6-fluoro-7-chloro-4-oxo-3-quinolinecarboxylic acid and 20.49 g (238 mmoles) of piperazine in 53 mL pyridine was heated at 100°C for 18 hours under nitrogen. The suspension was cooled at +5°C, the precipitate was filtered and washed with 5 mL pyridine and cold ether. The precipitate was taken up in 110 mL water and the pH adjusted to 7.2 with 6N hydrochloric acid. The precipitate was filtered and washed with cold water to give 14.16 g of crude product. The crude product was suspended in 823 mL 95% aqueous isopropanol. The suspension was heated to reflux and 3.20 mL (49.3 mmoles) of methanesulfonic acid was added. The mixture was kept at room temperature overnight, filtered and dried to yield 8.12 g of titled compound. mp > 270°C.

Method 2

20

A mixture of 0.3 g (1.01 mmole) 1-(1,1-dimethylethyl)-6-fluoro-7-chloro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid and 0.3 g (3.48 mmoles) piperazine in 1 mL pyridine was heated under reflux for 18 hours. After cooling the mixture was concentrated under reduced pressure. The residue was poured in 10mL of 10% acetic acid. After filtration of little insoluble the solution was taken to pH 6.5, saturated with brine and extracted three times with dichloromethane. After evaporation the resulting solid obtained was purified in water to give 0.15 g of 1-(1,1-dimethylethyl)-1,4-dihydro-6-fluoro-7-piperazinyl-4-oxo-3-quinolinecarboxylic acid purified as in method 1.

The following compounds were also prepared by following substantially the above procedure:

30.

EXAMPLE 27-[4-(CYCLOPENTEN-3-YL)-1-PIPERAZINYL]-1-(1,1-DIMETHYLETHYL)-4-OXO-3-QUINOLINECARBOXYLIC ACID, HYDROCHLORIDE1,4-DIHYDRO-6-FLUORO-4-OXO-3-QUINOLINECARBOXYLIC ACID, HYDROCHLORIDE

35

EXAMPLE 37-(8-METHYL-3,8-DIAZABICYCLO[3.2.1]OCTAN-3-YL)-1-(1,1-DIMETHYLETHYL)-1,4-DIHYDRO-6-FLUORO-4-OXO-3-QUINOLINECARBOXYLIC ACID, HYDROCHLORIDE. MP 308°C.EXAMPLE 47-[3-PHENYL]-1-PIPERAZINYL]-1-(1,1-DIMETHYLETHYL)-1,4-DIHYDRO-6-FLUORO-4-OXO-3-QUINOLINECARBOXYLIC ACID, METHANESULFONATE. MP > 300°C.EXAMPLE 5

50

7-(3-AMINO-3-METHYL-PYRROLIDIN-1-YL)-1-(1,1-DIMETHYLETHYL)-1,4-DIHYDRO-4-OXO-6-FLUORO-3-QUINOLINECARBOXYLIC ACID. MP>260°C

55

EXAMPLE 61-(1,1-DIMETHYLETHYL)-1,4-DIHYDRO-6-FLUORO-7-(4-METHYL-1-PIPERAZINYLM)-4-OXO-3-QUINOLINECARBOXYLIC ACID, HYDROCHLORIDE

5 A mixture of 1.4 g (4.7 mmoles) 1-(1,1-dimethylethyl)-1,4-dihydro-6,7-difluoro-4-oxo-3-quinolinecarboxylic acid and 2.08 mL (18.8 mmoles) N-methylpiperazine were heated at 100°C under nitrogen for 18 hours. The mixture was evaporated to dryness under reduced pressure. The residue was dissolved in water and the solution was adjusted to pH 6.5 - 7.0 with 5N hydrochloric acid. The precipitate was filtered and washed two times with water and once with ethanol to give 0.63 g crude material, which was recrystallized as its

10 hydrochloride in ethanol to give 0.54 g of the titled compound. MP > 270°C.

10 The following compounds were also prepared by following substantially the above procedure:

EXAMPLE 7:

15 7-(2,5-DIAZABICYCLO[2.2.2]OCTAN-2-YL)-1-(1,1-DIMETHYLETHYL)-1,4-DIHYDRO-6-FLUORO-4-OXO-3-QUINOLINECARBOXYLIC ACID. MP 164°C.

EXAMPLE 8:

20 7-(1S,4S-2,5-DIAZABICYCLO[2.2.1]HEPTAN-2-YL)-1-(1,1-DIMETHYL)-1,4-DIHYDRO-6-FLUORO-4-OXO-3-QUINOLINECARBOXYLIC ACID. MP 243°C. [α]<sup>D</sup> = -188° (C = 0.25, 0.1N HCl).

EXAMPLE 9:

25 7-(3-(AMINOMETHYL)-1-PYRROLIDINYL)-1-(1,1-DIMETHYLETHYL)-1,4-DIHYDRO-6-FLUORO-4-OXO-3-QUINOLINECARBOXYLIC ACID. MP 231°C.

EXAMPLE 10:

30 7-(3-(ETHYLAMINO)METHYL-1-PYRROLIDINYL)-1-(1,1-DIMETHYLETHYL)-1,4-DIHYDRO-6-FLUORO-4-OXO-3-QUINOLINECARBOXYLIC ACID

EXAMPLE 11:

35 7-(3-METHYL-1-PIPERAZINYLM)-1-(1,1-DIMETHYLETHYL)-1,4-DIHYDRO-6-FLUORO-4-OXO-3-QUINOLINECARBOXYLIC ACID

EXAMPLE 12:

40 7-((3,5-DIMETHYL)-1-PIPERAZINYLM)-(1,1-DIMETHYLETHYL)-1,4-DIHYDRO-6-FLUORO-4-OXO-3-QUINOLINECARBOXYLIC ACID. MP 197°C.

EXAMPLE 13:

45 7-(4-(DIMETHYLAMINO)-1-PIPERAZINYLM)-1-(1,1-DIMETHYLETHYL)-1,4-DIHYDRO-6-FLUORO-4-OXO-3-QUINOLINECARBOXYLIC ACID. MP 226°C.

EXAMPLE 14:

5      7-(1R,4R-2,5-DIAZABICYCLO[2.2.1]HEPTAN-2-YL)-1-(1,1-DIMETHYLETHYL)-1,4-DIHYDRO-6-FLUORO-4-OXO-3-QUINOLINECARBOXYLIC ACID. MP 250°C.  $[\alpha]^\text{D} = +172^\circ$  (C = 0.25% 0.1N HCl).

EXAMPLE 15:

10      7-(4-(1,1-DIMETHYLETHYL)-1-PIPERAZINYL)-1-(1,1-DIMETHYLETHYL)-1,4-DIHYDRO-6-FLUORO-4-OXO-3-QUINOLINECARBOXYLIC ACID

15      A mixture of 0.45 g (1.51 mmoles) 1-(1,1-dimethylethyl)-1,4-dihydro-7-chloro-6-fluoro-4-oxo-3-quinolinecarboxylic acid and 0.65 g (4.56 mmoles) 1-(1,1-dimethylethyl)piperazine in 2 mL N-methylpyrrolidone were heated 5 hours at 100°C. The solvent was evaporated under reduced pressure. The residue was triturated in water. The precipitate was recrystallized in ethanol to give 0.136 g of titled compound. MP > 270°C.

EXAMPLE 16:

20      7-PIPERAZINYL-1-(1,1-DIMETHYLETHYL)-1,4-DIHYDRO-6,8-DIFLUORO-4-OXO-3-QUINOLINECARBOXYLIC ACID

25      To a refluxing solution of 0.87 g (10 mmoles) piperazine in 15 mL acetonitrile was added portionwise 1,10 g (3.36 mmoles) of 1-(1,1-dimethylethyl)-1,4-dihydro-6,7,8-trifluoro-4-oxo-3-quinoline carboxylic acid ethyl ester in 15 minutes. The mixture was refluxed 7 hours, cooled and evaporated to dryness. The residue was worked up with dichloromethane and brine to give 0.89 g of crystalline product which was used without further purification.

30      0.805 g (2.04 mmoles) of 7-piperazinyl-1-(1,1 dimethylethyl)-1,4-dihydro-6,8-difluoro-4-oxo-3-quinolinecarboxylic acid ethyl ester was hydrolyzed with 1.05 mL 2N NaOH for two hours. The solution was evaporated to dryness neutralized with 5% acetic acid (pH 7.0). The solid was filtered to give 0.585 g of titled compound.

35      The following compounds were also prepared by following substantially the above procedure.

EXAMPLE 17:

35      7-(3-(ETHYLAMINO)METHYL-1-PYRROLIDINYL)-1-(1,1-DIMETHYLETHYL)-1,4-DIHYDRO-6,8-DIFLUORO-4-OXO-3-QUINOLINECARBOXYLIC ACID

EXAMPLE 18:

40      7-(1R,4R-2,5-DIAZABICYCLO[2.2.1]HEPTAN-2-YL)-1-(1,1-DIMETHYLETHYL)-1,4-DIHYDRO-6,8-DIFLUORO-4-OXO-3-QUINOLINECARBOXYLIC ACID. MP > 260°C.

EXAMPLE 19:

45      7-(3-AMINO-1-PYRROLIDINYL)-1-(1,1-DIMETHYLETHYL)-1,4-DIHYDRO-6-FLUORO-4-OXO-3-QUINOLINECARBOXYLIC ACID, HYDROCHLORIDE

50      A mixture of 800 mg (2.13 mmoles) 1-(1,1-dimethylethyl)-1,4-dihydro-6,7-difluoro-4-oxo-3-quinolinecarboxylic acid, 700 mg (3.2 mmoles) of 3-trifluoroacetylamo pyrrolidine hydrochloride and 1.3 mL (8.5 mmoles) of 1,8-diazabicyclo[5.4.0]undec-7-ene in 3 mL pyridine was stirred 30 minutes at room temperature, evaporated to dryness and poured into water. The pH was adjusted to 7.5 with 1N hydrochloric acid. The precipitate was filtered to give 430 mg of 7-(3-trifluoroacetylamo-1-pyrrolidinyl)-1-(1,1-dimethylethyl)-1,4-dihydro-6-fluoro-4-oxo-3-quinolinecarboxylic acid. mp.200°C dec. 409 mg (0.92 mmole) of that compound was suspended in 2 mL 1N NaOH and refluxed 2 hours. The solution was cooled and diluted with water, the pH was adjusted to 7.5 with 10% acetic acid. The precipitate was filtered, washed with water, dried and recrystallized as an hydrochloride in ethanol to give 180 mg of titled compound. MP > 270°C.

SEARCHED 8/6/90006

EXAMPLE 207-PIPERAZINYL-1-(1,1-DIMETHYLETHYL)-1,4-DIHYDRO-6-FLUORO-4-OXO-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID

5 To a refluxed solution of 487 mg (5.65 mmoles) piperazine in 30 mL acetonitrile was gradually added 612 mg (1.87 mmole) of 1-(1,1-dimethylethyl)-1,4-dihydro-6-fluoro-7-chloro-4-oxo-1,8-naphthyridine-3-carboxylic acid ethyl ester over a 10 mn period. The solution was refluxed 30 minutes and evaporated to dryness. The residue was taken up in water and filtered to give 435 mg of 7-piperazinyl-1-(1,1-dimethylethyl)-1,4-dihydro-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid ethyl ester.

10 This ester 400 mg (1.06 mmoles) was suspended in 1 mL water, 1.9 mL 1N aqueous sodium hydroxide was added. The suspension was refluxed 30 minutes. The solution was cooled and adjusted to pH 7.5 with 1N hydrochloric acid. The precipitate was filtered and washed with water. The crude product was recrystallized in water to give 248 mg of titled compound. MP > 270°C.

15 The following compounds were also prepared by following substantially the above procedure.

16

EXAMPLE 21:7-(3-METHYL-1-PIPERAZINYL)-1-(1,1-DIMETHYLETHYL)-1,4-DIHYDRO-6-FLUORO-4-OXO-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACIDEXAMPLE 22:7-(1S,4S-2,5-DIAZABICYCLO[2.2.1]HEPTAN-2-YL)-1-(1,1-DIMETHYLETHYL)-1,4-DIHYDRO-6-FLUORO-4-OXO-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID.

MP 250°C,  $[\alpha]^D = -196^\circ$  (c = 0.25, 0.1N HCl)

EXAMPLE 23:7-(1S,4S-2,5-DIAZABICYCLO[2.2.2]OCTAN-2-YL)-1-(1,1-DIMETHYLETHYL)-1,4-DIHYDRO-6-FLUORO-4-OXO-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID. MP 268°C.

35

EXAMPLE 24:7-(4-(CYCLOPENTEN-3-YL)-1-PIPERAZINYL)-1-(1,1-DIMETHYLETHYL)-1,4-DIHYDRO-6-FLUORO-4-OXO-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID. MP 222°C.

40

EXAMPLE 25:7-(3-(AMINOMETHYL)-1-PYRROLIDINYL)-1-(1,1-DIMETHYLETHYL)-1,4-DIHYDRO-6-FLUORO-4-OXO-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID. MP 254°C.EXAMPLE 26:7-(3-((ETHYLAMINO)METHYL)-1-PYRROLIDINYL)-1-(1,1-DIMETHYLETHYL)-1,4-DIHYDRO-6-FLUORO-4-OXO-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID. MP 254°C.EXAMPLE 27:7-(3-METHYL-1-PIPERAZINYL)-1-(1,1-DIMETHYLETHYL)-1,4-DIHYDRO-6-FLUORO-4-OXO-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID. MP 205°C.

EXAMPLE 28:

7-(3,4-DIMETHYL-1-PIPERAZINYLYL)-1-(1,1-DIMETHYLETHYL)-1,4-DIHYDRO-6-FLUORO-4-OXO-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID. MP 204°C.

5

EXAMPLE 29:

7-(3-PHENYL-1-PIPERAZINYLYL)-(1,1-DIMETHYLETHYL)-1,4-DIMETHYLETHYL)-1,4-DIHYDRO-6-FLUORO-4-OXO-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID, METHANESULFONATE.

EXAMPLE 30:

7-(1R,4R-2,5-DIAZABICYCLO[2.2.1]HEPTAN-2-YL)-1-(1,1-DIMETHYLETHYL)-1,4-DIHYDRO-6-FLUORO-4-OXO-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID.

To a suspension of 440 mg (1.69 mmoles) 1R,4R-2,5-diazabicyclo[2.2.1]heptane, dihydrobromide and 418 mg (1.28 mmoles) 1-(1,1-dimethylethyl)-1,4-dihydro-6-fluoro-7-chloro-4-oxo-1,8-naphthyridine-3-carboxylic acid ethyl ester in 8 mL pyridine was added 0.67 g (4.4 mmoles) 1,8-diazabicyclo[5.4.0]undec-7-ene.

20 The solution was refluxed 4 hours, evaporated to dryness under reduced pressure. The residue was taken in cold water. The precipitate was filtered to give 193 mg of 7-(1R,4R-2,5-diazabicyclo[2.2.1]heptan-2-yl)-1-(1,1-dimethylethyl)-1,4-dihydro-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid ethyl ester.

This ester 193 mg (without further purification) was suspended in 1.96 mL 1N aqueous sodium hydroxide and refluxed 30 minutes. The solution was cooled and brought to pH 7.5 with 6N hydrochloric acid. The precipitate was filtered and washed three times with water and two times with ether to give 170 mg of titled compound. MP 250°C.  $[\alpha]^D = + 173^\circ$  (c = 0.25, 0.1N HCl) Methanesulfonate salt, MP 304°C,  $[\alpha]^D = + 158.6^\circ$  (c = 0.25, 0.1N HCl).

EXAMPLE 31:

The following compound was prepared by following substantially the procedure of Example 30:

7-(1R,4R-5-METHYL-2,5-DIAZABICYCLO[2.2.1]HEPTAN-2-YL)-1-(1,1-DIMETHYLETHYL)-1,4-DIHYDRO-6-FLUORO-4-OXO-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID

35 The following compound was also prepared by the above procedure of Example 30 except that the condensation step lasted 24 hours:

EXAMPLE 32:

40

7-(8-METHYL-3,8-DIAZABICYCLO[3.2.1]OCTAN-3-YL)-1-(1,1-DIMETHYLETHYL)-1,4-DIHYDRO-6-FLUORO-4-OXO-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID, METHANESULFONATE SALT.

EXAMPLE 33:

7-(3,8-DIAZABICYCLO[3.2.1]OCTAN-3-YL)-1-(1,1-DIMETHYLETHYL)-1,4-DIHYDRO-6-FLUORO-4-OXO-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID, METHANESULFONATE

A mixture of 653 mg (2 mmoles) 1-(1,1-dimethylethyl)-1,4-dihydro-6-fluoro-7-chloro-4-oxo-1,8-naphthyridine-3-carboxylic acid ethyl ester and 732 mg (3 mmoles) 8-trifluoroacetyl-3,8-diazabicyclo[3.2.1]-octan, hydrochloride and 985 mg (6.48 mmoles) 1,8-diazabicyclo[5.4.0]undec-7-ene in 30 mL acetonitrile was heated at 80°C for 72 hours. The solution was cooled and evaporated to dryness. The residue was worked up with dichloromethane and water. The organic layer was dried over magnesium sulfate and evaporated to give an oil. Purification was achieved by silicagel column chromatography to obtain 220 mg of 7-(8-trifluoroacetyl-3,8-diazabicyclo[3.2.1]octan-3-yl)-1-(1,1-dimethylethyl)-1,4-dihydro-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid ethyl ester. MP 205°C.

The above ester (200 mg) was suspended in 1.64 mL 1N aqueous sodium hydroxyde for three hours. The solution was cooled and the pH adjusted to 7.4 with 2N hydrochloric acid. The precipitate was filtered, dissolved in 25 mL methanol, 27  $\mu$ L methanesulfonic acid was added, the suspension was heated to reflux, filtered while hot, cooled. The precipite was filtered to give 100 mg of titled compound. MP 300°C.

5

EXAMPLE 34:

The following compound was also prepared by the above procedure except that after alkaline hydrolysis 10 and the pH adjusted to 7.4, the solution, after filtration, was evaporated to dryness. The residue was recrystallized in a mixture of isopropanol-ethanol 60/40:

7-(2-AMINOMETHYL-MORPHOLIN-4-YL)-1-(1,1-DIMETHYLETHYL)-1, 4-DIHYDRO-6-FLUORO-4-OXO-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID.

15

EXAMPLE 35:

The following compound was prepared by following substantially the procedure of Example 33: 10 7-(3-AMINO-3-METHYL-PYRROLIDIN-1-YL)-1-(1,1-DIMETHYLETHYL)-6-FLUORO-1,4-DIHYDRO-4-OXO-1,8-NAPHTHYRIDINE-3-CARBOXYCLIC ACID. MP >260°C

EXAMPLE 36:

25 7-(3-AMINO-1-PYRROLIDINYL)-1-(1,1-DIMETHYLETHYL)-1,4-DIHYDRO-6-FLUORO-4-OXO-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID

To a suspension of 327 mg (1 mmole) 1-(1,1-dimethylethyl)-1,4-dihydro-6-fluoro-7-chloro-4-oxo-1,8-naphthyridine-3-carboxylic acid ethyl ester in 33 mL acetonitrile was added successively 615 mg. (3 mmoles) of 3-trifluoroacetylarnino-pyrrolidine, hydrochloride and 415 mg (3 mmoles) anhydrous potassium 30 carbonate. The suspension was stirred overnight and evaporated to dryness. The residue was taken up in 7 mL water, filtered and washed three times with 5 mL water recrystallized in ethanol to give 400 mg of 7-(3-trifluoroacetylarnino-1-(1-pyrrolidinyl))-1-(1,1-dimethylethyl)-1,4-dihydro-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid ethyl ester. MP 240°C.

This ester (370 mg - 0.78 mmole) was suspended in 3.1 mL 1N aqueous sodium hydroxide and 35 refluxed one hour. The solution was cooled and adjusted to pH 7.8 with 1N HCl. The precipitate was filtered and washed with water to give 250 mg of titled compound. MP 260°C dec.

40

EXAMPLE 37

7-(3-FLUOROMETHYL-PIPERAZIN-4-YL)-1-(1,1-DIMETHYLETHYL)-1,4-DIHYDRO-6-FLUORO-4-OXO-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID

This compound was prepared by following substantially the procedure of example 33 except the reaction lasted one hour.

45

EXAMPLE 38

50 7-(3-AMINOMETHYL-PIPERAZIN-4-YL)-1-(1,1-DIMETHYLETHYL)-1,4-DIHYDRO-6-FLUORO-4-OXO-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID

This compound was prepared by following substantially the procedure of example 32.

55

EXAMPLE 39

7-(3-FLUOROMETHYL-PIPERAZIN-4-YL)-1-(1,1-DIMETHYLETHYL)-1,4-DIHYDRO-6-FLUORO-4-OXO-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID

This compound was prepared according to example 19.

EXAMPLE 407-(1,4-DIAZABICYCLO[3.2.1]OCT-4-YL)-1-(1,1-DIMETHYLETHYL)-1,4-DIHYDRO-6-FLUORO-4-OXO-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID

5 This compound was prepared according to example 36. (The condensed amine was prepared by following the procedure described by P.A. STURM, M. CORY, D.W. HENRY, J.W. McCALL and J.B. ZIEGLER in J. Med. Chem. 1977, 20, 1333).

EXAMPLE 417-(3,8-DIAZABICYCLO [3.2.1] OCT-8-YL)-1-(1,1-DIMETHYLETHYL)-1,4-DIHYDRO-6-FLUORO-4-OXO-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID

15 a) 7-(3-benzyl-3,8-diazabicyclo [3.2.1] oct-8-yl)-1-(1,1-dimethylethyl)-1,4-dihydro-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid ethyl ester was mainly obtained according to procedure described in example 33 by condensing 3-benzyl-3,8-diazabicyclo [3.2.1] octane, dihydrochloride with the corresponding 1-(1,1-dimethylethyl) naphthyridine in presence of 1,8-diazabicyclo [5.4.0] undec-7-ene in acetonitrile.  
 b) This benzyl product was hydrogenized in methanol in presence of 10% palladium on carbon to give 7-(3,8-diazabicyclo [3.2.1] oct-8-yl)-1-(1,1-dimethylethyl)-1,4-dihydro-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid ethyl ester which was hydrolyzed according to the procedure described in example 33 to give the title compound.

EXAMPLE 427-(3-AMINO-4-METHYL-1-PYRROLIDINYL)-1-(1,1-DIMETHYLETHYL)-1,4-DIHYDRO-6-FLUORO-4-OXO-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID

(CIS and TRANS MIXTURE)

30 This compound was obtained as described in example 36. M.P. 270°C.

EXAMPLE 437-(4-AMINOMETHYL-3-HYDROXY-1-PYRROLIDINYL)-1-(1,1-DIMETHYLETHYL)-1,4-DIHYDRO-6-FLUORO-4-OXO-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID HYDROCHLORIDE

35 This compound was obtained according to the procedure described in example 33.

EXAMPLE 447-(4-AMINOMETHYL-3-HYDROXY-1-PYRROLIDINYL)-1-(1,1-DIMETHYLETHYL)-1,4-DIHYDRO-6-FLUORO-4-OXO-QUINOLINE-3-CARBOXYLIC ACID

40 This compound was obtained as described in example 19.

45 PREPARATION OF NEW AMINES

EXAMPLE A50 1-(4-TOLUENESULFONYL)-4-HYDROXY-D-PROLINE ETHYL ESTER

To a cold solution of 10 g (50 mmoles) of 4-hydroxy-D-proline ethyl ester, hydrochloride (prepared according to G. L. BAKER; S. J. FRITSCHEL; J. R. STILLE and J. K. STILLE; J. Org. Chem. 1981, 46, 2954) in 100 mL dry pyridine at +5°C was added portionwise 10.66 g (56 mmoles) of 4-toluenesulfonyl chloride.

55 The resulting dark solution was stirred 24 h at +5°C and evaporated to dryness. The residue was taken up in 2000 mL dichloromethane and was washed with 2N hydrochloric acid then with water. The organic layer was dried over MgSO<sub>4</sub>, filtered and evaporated to dryness. The oily residue was crystallized in diisopropyl ether to yield 13.70 g of titled compound. MP 78°C.  $[\alpha]^{20} = +79.39^\circ$  (c = 1.8, ethanol)

1-(4-TOLUENESULFONYL)-4-(4-TOLUENESULFONYLOXY)-D-PROLINE ETHYL ESTER

5 To a cold solution of 11.85 g (38 mmoles) 1-(4-toluenesulfonyl)-4-hydroxy-D-proline ethyl ester in 37 mL pyridine at 0°C was added 8.0 g (41 mmoles) of 4-toluenesulfonyl chloride portionwise in 15 minutes. The cold solution was stirred one hour at 0°C and then 48 h at room temperature. Water (100 mL) was added dropwise in the solution cooled at 0°C which was stirred 30 minutes at 0°C. The precipitate was filtered and washed with cold water and ether to give 15.55 g of titled compound. MP 122°C.  $[\alpha]^D = +26.36^\circ$  (c = 2, chloroform)

10 1-(4-TOLUENESULFONYL)-4-(4-TOLUENESULFONYLOXY-2-HYDROXYMETHYL)PYRROLIDINE

15 To a stirred solution of 4.67 g (10 mmoles) 1-(4-toluenesulfonyl)-4-(4-toluenesulfonyloxy)-D-proline ethyl ester in 45 mL tetrahydrofuran at 0°C was added 0.77 g (35 mmoles) of lithium borohydride. The suspension was stirred one hour at 0°C and then one hour at room temperature. More lithium borohydride 0.15 g (6.9 mmoles) was added and the suspension was stirred overnight at room temperature. The suspension was cooled at 0°C and 5N hydrochloric acid was added dropwise until no gas released. The suspension was evaporated to dryness under reduced pressure. The residue was taken up in water and ethylacetate. The organic layer was washed with little water and brine, dried over  $\text{MgSO}_4$  and evaporated to dryness under reduced pressure to afford 4.16 g of titled compound.

20 MP 93°C;  $[\alpha]^D = +14^\circ$  (c = 2, ethanol)

25 1-(4-TOLUENESULFONYL)-2-(4-TOLUENESULFONYLOXYMETHYL)-4-(4-TOLUENESULFONYLOXY)-PYRROLIDINE

30 To a cooled solution of 1.83 g (9.6 mmoles) 4-toluenesulfonyl chloride in 10 mL pyridine at +10°C was added 3.40 g (8 mmoles) of 1-(4-toluenesulfonyl)-2-hydroxymethyl-4-(4-toluenesulfonyloxy)-pyrrolidine and the mixture was stirred 18 hours. The solution obtained was then poured into 50 mL ice-cooled 2N hydrochloric acid. The precipitate was filtered, washed with water and ether. The crystalline product was purified in boiling water and ether. The crystalline product was purified in boiling ethanol to give 3.94 g of titled compound. MP 153°C  $[\alpha]^D = +46.7^\circ$  (c = 1.9, acetone)

35 1R,4R-2-(4-TOLUENESULFONYL)-5-PHENYLMETHYL-2,5-DIAZABICYCLO-(2.2.1)HEPTANE

40 A mixture of 3.6 g (6.2 mmoles) 1-(4-toluenesulfonyl)-2-(4-toluenesulfonyloxy)methyl-4-(4-toluenesulfonyloxy)-pyrrolidine and 1.99 g (18 mmoles) of benzylamine in 12 mL toluene was heated under reflux for 72 hours. The mixture was cooled, the benzylamine toluenesulfonate was filtered off. The filtrate was evaporated to dryness and flash chromatographed with dichloromethane-ethyl acetate 70:30 to yield 0.74 g titled compound. mp 118°C;  $[\alpha]^D = +13.9^\circ$  (c = 0.4, chloroform)

45 1R,4R-5-PHENYLMETHYL-2,5-DIAZABICYCLO-(2.2.1)HEPTANE, DIHYDROBROMIDE

50 To a hot solution of 17 mL hydrobromic acid 33% in acetic acid at 70°C was added 1 g (2.9 mmoles) of 1R,4R-2-(4-toluenesulfonyl)-5-phenylmethyl-2,5-diazabicyclo (2.2.1) heptane. The solution was stirred for 12 hours at 70°C. The suspension was cooled and concentrated to one third, cooled to 10°C. The precipitate was filtered, washed with acetic acid and acetone to afford 0.9 g of titled compound. MP 275°C;  $[\alpha]^D = -0.38^\circ$  (c = 1,  $\text{H}_2\text{O}$ )

55 1R,4R-2,5-DIAZABICYCLO-(2.2.1)HEPTANE, DIHYDROBROMIDE

60 A suspension of 6.6g (18.8 mmoles) 1R,4R-5-phenylmethyl-2,5-diazabicyclo(2.2.1)heptane dihydrobromide and 3.0 g 10% Pd on C was hydrogenated at atmospheric pressure. The reaction was complete in about 4 hours. The catalyst was filtered off and the filtrate was evaporated. The residue was slurred in ethanol, filtered to give 4.34 g of titled compound.  $[\alpha]^D = -20.4^\circ$  (c = 1.2, 0.1N HCl)

EXAMPLE B2-(N-PHTHALIMIDE)METHYL-4-PHENYLMETHYLMORPHOLINE

5 A suspension of 6.42 g (28.4 mmoles) 2-chloromethyl-4-phenylmethyl morpholine (prepared according to F. LOFTUS, Synth. Communications, 10 (1), 59 (1980)) and 5.18 g (28.0 mmoles) of potassium phthalimide in 15 mL dry dimethylformamide were stirred 48 hours at 120-130°C. The suspension was cooled and poured into ice-water, extracted twice with ethyl acetate, washed with brine, dried over MgSO<sub>4</sub>. The residue was recrystallized from isopropanol to yield 6.54 g of titled compound. MP 133°C.

10

2-AMINOMETHYL-4-PHENYLMETHYLMORPHOLINE

15 A suspension of 3.36 g (10 mmoles) 2-(N-phthalimido)methyl-4-phenyl methylmorpholine was refluxed with 1.25 g (25 mmoles) of hydrazine hydrate 85% in 50 mL ethanol for two hours. The suspension was cooled and then filtered off. The filtrate was evaporated to dryness, taken up with ether, filtered again and the filtrate concentrated under vacuum to give 2.05 g of titled compound as an yellow oil.

20 2-(N-TRIFLUOROACETYL)AMINOMETHYL-4-PHENYLMETHYLMORPHOLINE

25 A mixture of 6.18g (30 mmoles) 2-aminomethyl-4-phenylmethylmorpholine and 20 mL trifluoroacetic anhydride was refluxed 15 minutes. The mixture was cooled, and evaporated to dryness. The residue was taken up in ethyl acetate, washed with ice cooled 1N aqueous sodium hydroxyde, water and brine, dried over MgSO<sub>4</sub> and evaporated to dryness. The residue was crystallized in ether to afford 7.84 g of titled compound. MP 118°C.

2-(N-TRIFLUOROACETYL)AMINOMETHYL-MORPHOLINE, HYDROCHLORIDE

30 A suspension of 7.92 g (26.2 mmoles) 2-(trifluoroacetyl)aminomethyl-4-phenylmethyl morpholine and 1.7g 10% Pd on C was hydrogenated at atmospheric pressure. The reaction was complete in about 3 hours. The catalyst was filtered off and the filtrate was evaporated to dryness and 4.92 mL ethanolic 5N hydrochloric acid was added to the oily product in 50mL ethanol. The solution was evaporated to dryness and crystallized by scratching in ether to yield 4.19 g of crude product which was recrystallized in isopropanol to give 2.82 g of titled compound. MP 186°C.

EXAMPLE C40 3-BENZYL-2,4-DIOXO-3,8-DIAZABICYCLO(3.2.1)OCTANE

45 A mixture of 3-benzyl-2,4-dioxo-8-methyl-3,8-diazabicyclo(3.2.1)octane (US Pat. 3,328,396) (1.05 g) and pyridinium hydrochloride (5 g) was heated in an oil-bath at 220°C for 25 minutes. After cooling, the mixture was taken up with water (30 mL) and extracted with ether. The organic layer was dried over magnesium sulfate, evaporated to give 0.45 g of crude product which was chromatographed over silica gel using dichloromethane - ethyl acetate 80:20 as eluent to give 0.3 g of crystallized titled product. MP 72°C.

50 3-BENZYL-3,8-DIAZABICYCLO(3.2.1)OCTANE

55 A solution of 3-benzyl-2,4-dioxo-8-methyl-3,8-diazabicyclo (3.2.1)octane (2.05 g, 8.91 mmoles) in dry ether (100 mL) was treated gradually with lithium aluminum hydride (1.52 g, 4 mmoles), heated under reflux for one hour, and hydrolyzed successively with 50 mL of water-saturated ether and then 10 mL of water. This mixture was filtered on a celite pad. The filtrate was dried over magnesium sulfate and then evaporated to give the crude titled product which was used without any purification for further uses.

2006 RELEASE UNDER E.O. 14176

3-BENZYL-8-TRIFLUOROACETYL-3,8-DIAZABICYCLO(3.2.1)OCTANE, HYDROCHLORIDE

Trifluoroacetic acid anhydride (4.6 mL) was added to ice-cooled 3-benzyl-3,8-diazabicyclo(3.2.1)-octane (1.4 g, 6.9 mmoles). The resulting mixture was heated under reflux for 15 minutes, cooled, diluted with ethanol (20 mL) and treated with 2 mL of 5N hydrochloric acid in ethanol, evaporated to dryness. The so-obtained solid was taken-up with ether, collected by filtration, and dried in vacuo to afford 1.6 g of titled compound. MP 176°C.

10 8-TRIFLUOROACETYL-3,8-DIAZABICYCLO(3.2.1)OCTANE

A solution of the 3-benzyl-8-trifluoroacetyl-3,8-diazabicyclo-(3.2.1)octane hydrochloride in 50 mL of methanol was hydrogenated at atmospheric pressure in the presence of 10% Pd/C (0.5 g) until the theoretical quantity of hydrogen was absorbed. The mixture was filtered and the filtrate was evaporated to dryness to yield 1.08 g of titled compound as a white solid. MP 224°C (dec).

EXAMPLE D20 1-(CYCLOPENTEN-3-YL)PIPERAZINE

3-chlorocyclopentene (306 mmoles, 36.9 g) was added dropwise to a solution of anhydrous piperazine (496 mmoles, 36.9 g) in dry methanol (350 mL) at -13°C. The final solution was stirred at -13°C for 15 minutes and at room temperature for one hour. The solvent was evaporated to dryness, and the residue was first taken up with chloroform and then filtered to eliminate the precipitate. After elimination of chloroform by evaporation the filtrate give 10 g of 1-(cyclopenten-3-yl) piperazine (yellow oil).

EXAMPLE E30 2-CARBOXYETHYL-1,4-DI-PHENYLMETHYL PIPERAZINE

To a solution of 43.29 g (166.0 mmol) of ethyl 2,3-dibromopropionate in 145 ml of benzene warmed at 40°C was added dropwise a solution of 40 g (166.0 mmol) of N,N'-dibenzylethylenediamine and 46.2 ml (166.0 mmol) of triethylamine in 40 ml of benzene. The vigorous stirred suspension was heated under reflux overnight, cooled and filtered. The benzene layer was washed three times with 50 ml of water. The organic layer was dried over magnesium sulfate. After evaporation 58.95 g of a thick oil was obtained which was purified by chromatography using dichloromethane/ethyl acetate (90:10) to yield 50.4 g (89.7%) of title compound.

40

2-HYDROXYMETHYL-1,4-DI-PHENYLMETHYL PIPERAZINE

In a dry flask were carefully placed 5.67 g (150 mmol) of lithium aluminum hydride to which were added 110 ml of absolute ether. The suspension was flushed with nitrogen and cooled to -5°C. Then a solution of 25 g (73.0 mmol) of 2-carboxyethyl-1,4-di-phenylmethyl piperazine in 110 ml of absolute ether was added dropwise. After complete addition the suspension was heated under reflux for three hours, cooled in an ice-bath. Excess of hydride was carefully destroyed with 6.3 ml of water. Insoluble material was filtered off and the ether layer was washed with water and dried over magnesium sulfate. After removing of the solvent it was obtained 18.85 g. (86%) of title compound. MP 77°C.

2-FLUOROMETHYL-1,4-DI-PHENYLMETHYL PIPERAZINE

55 To a solution of 0.6 g (3.7 mmol) of diethylamino-sulfur trifluoride in 5 ml dichloromethane cooled at -78°C under nitrogen was added dropwise a solution of 1 g (3.4 mmol) of 2-hydroxymethyl-1,4-di-phenylmethyl piperazine in 5 ml dichloromethane. The temperature of the solution was allowed to warm to -50°C in 30 mn then to 0°C in 1hr 30 min. The solution was stirred two more hours at room temperature

and cooled back to +5°C. A few drops of aqueous saturated solution of sodium bicarbonate were added until basic pH. The organic layer was washed twice with water, dried over magnesium sulfate, the solvent removed to give 1.10 g of an oil which was purified by chromatography using dichloromethane/ethyl acetate (95:5) to afford 0.46 g (42%) of title compound.

5

#### 2-FLUOROMETHYL-PIPERAZINE, DIHYDROCHLORIDE

A solution of 0.44 g (1.47 mmol) of 2-fluoromethyl-1,4-di-phenylmethyl piperazine in 20 ml ethanol was 10 hydrogenized over 0.2 g of 10% palladium on carbon for 4 hours. The catalyst was filtered over a celite pad, washed with water. To the filtrate was added 3.2 ml of 1N aqueous hydrochloric acid. The solution was evaporated to dryness, taken up twice with absolute ethanol. The residue was crystallized in the minimum amount of absolute ethanol to give 0.22 g of white crystals of title compound (69%). M.P. 232°C.

15

#### EXAMPLE F

#### 2-CHLOROMETHYL-1,4-DI-PHENYLMETHYL PIPERAZINE

20 A suspension of 23 g (62.3 mmol) of 2-hydroxymethyl-1,4-di-phenylmethyl piperazine, dihydrochloride in 79 ml thionyl chloride was heated 4 hours under reflux. The solution was cooled and excess thionyl chloride was evaporated under reduced pressure. The residue was crystallized in ethanol, dried with acetone to yield 19.5 g of title compound dihydrochloride M.P. 234°C dec.

25 A suspension of this dihydrochloride in 130 ml 1N aqueous sodium hydroxide was stirred with 75 ml dichloromethane, the aqueous layer back washed three times with 75 ml dichloromethane. The organic layers were collected and dried over magnesium sulfate to give after evaporation 15.44 g (78%) of title compound.

#### 30 2-PHTALIMIDOMETHYL-1,4-DI-PHENYLMETHYL PIPERAZINE

A suspension of 15 g (47.6 mmol) of 2-chloromethyl-1,4-diphenylmethyl piperazine and 8.81 g (47.6 mmol) of potassium phtalimide in 7 ml anhydrous dimethyl formamide was stirred 2 hours at 110°C. After cooling the reaction mixture was taken up with 100 ml ethyl acetate. The mineral salts were filtered off. The 35 solvent was removed, the residue was dissolved in 150 ml ethyl acetate, washed three times with water, dried over magnesium sulfate to give a crystalline product which was recrystallized in isopropyl ether to yield 6.87 g (33%) of title compound. M.P. 124°C.

#### 40 2-AMINOMETHYL-1,4-DI-PHENYLMETHYL PIPERAZINE

The solution of 4.25 g (10 mmol) of 2-phtalimidomethyl-1,4-di-phenylmethyl piperazine and 1.25 g (25 mmol) of hydrazine monohydrate in 50 ml ethanol was stirred 2 hours under reflux. Insoluble material was filtered off. The ethanol layer was evaporated to dryness to afford a residue taken up in 20 ml ethyl ether, 45 filtered again and evaporated to give 3.0 g of the title compound as an oil.

#### 2-TRIFLUOROACETYLAMINOMETHYL-1,4-DI-PHENYLMETHYL PIPERAZINE, DIHYDROCHLORIDE

50 A suspension of 2.9 g (10 mmol) of 2-aminomethyl-1,4-di-phenylmethyl piperazine in 10 ml of trifluoroacetic anhydride was heated to reflux for 15 mn, cooled and evaporated to dryness. The residue was taken up in 40 ml ethanol and 5 ml 5N hydrochloric acid in ethanol. The solution was evaporated to dryness. The residue was triturated in 30 ml ethyl ether, the crystals were filtered and dried to give 3.98 g raw material, which was purified by dissolving impurities in hot acetone to yield 3.11 g of the title 55 compound.

2025 2627 2728 2829 2930 3031 3132 3233 3334 3435 3536 3637 3738 3839 3940 4041 4142 4243 4344 4445 4546 4647 4748 4849 4950 5051 5152 5253 5354 5455 5556 5657 5758 5859 5960 6061 6162 6263 6364 6465 6566 6667 6768 6869 6970 7071 7172 7273 7374 7475 7576 7677 7778 7879 7980 8081 8182 8283 8384 8485 8586 8687 8788 8889 8990 9091 9192 9293 9394 9495 9596 9697 9798 9899 99100 100101 101102 102103 103104 104105 105106 106107 107108 108109 109110 110111 111112 112113 113114 114115 115116 116117 117118 118119 119120 120121 121122 122123 123124 124125 125126 126127 127128 128129 129130 130131 131132 132133 133134 134135 135136 136137 137138 138139 139140 140141 141142 142143 143144 144145 145146 146147 147148 148149 149150 150151 151152 152153 153154 154155 155156 156157 157158 158159 159160 160161 161162 162163 163164 164165 165166 166167 167168 168169 169170 170171 171172 172173 173174 174175 175176 176177 177178 178179 179180 180181 181182 182183 183184 184185 185186 186187 187188 188189 189190 190191 191192 192193 193194 194195 195196 196197 197198 198199 199200 200201 201202 202203 203204 204205 205206 206207 207208 208209 209210 210211 211212 212213 213214 214215 215216 216217 217218 218219 219220 220221 221222 222223 223224 224225 225226 226227 227228 228229 229230 230231 231232 232233 233234 234235 235236 236237 237238 238239 239240 240241 241242 242243 243244 244245 245246 246247 247248 248249 249250 250251 251252 252253 253254 254255 255256 256257 257258 258259 259260 260261 261262 262263 263264 264265 265266 266267 267268 268269 269270 270271 271272 272273 273274 274275 275276 276277 277278 278279 279280 280281 281282 282283 283284 284285 285286 286287 287288 288289 289290 290291 291292 292293 293294 294295 295296 296297 297298 298299 299300 300301 301302 302303 303304 304305 305306 306307 307308 308309 309310 310311 311312 312313 313314 314315 315316 316317 317318 318319 319320 320321 321322 322323 323324 324325 325326 326327 327328 328329 329330 330331 331332 332333 333334 334335 335336 336337 337338 338339 339340 340341 341342 342343 343344 344345 345346 346347 347348 348349 349350 350351 351352 352353 353354 354355 355356 356357 357358 358359 359360 360361 361362 362363 363364 364365 365366 366367 367368 368369 369370 370371 371372 372373 373374 374375 375376 376377 377378 378379 379380 380381 381382 382383 383384 384385 385386 386387 387388 388389 389390 390391 391392 392393 393394 394395 395396 396397 397398 398399 399400 400401 401402 402403 403404 404405 405406 406407 407408 408409 409410 410411 411412 412413 413414 414415 415416 416417 417418 418419 419420 420421 421422 422423 423424 424425 425426 426427 427428 428429 429430 430431 431432 432433 433434 434435 435436 436437 437438 438439 439440 440441 441442 442443 443444 444445 445446 446447 447448 448449 449450 450451 451452 452453 453454 454455 455456 456457 457458 458459 459460 460461 461462 462463 463464 464465 465466 466467 467468 468469 469470 470471 471472 472473 473474 474475 475476 476477 477478 478479 479480 480481 481482 482483 483484 484485 485486 486487 487488 488489 489490 490491 491492 492493 493494 494495 495496 496497 497498 498499 499500 500501 501502 502503 503504 504505 505506 506507 507508 508509 509510 510511 511512 512513 513514 514515 515516 516517 517518 518519 519520 520521 521522 522523 523524 524525 525526 526527 527528 528529 529530 530531 531532 532533 533534 534535 535536 536537 537538 538539 539540 540541 541542 542543 543544 544545 545546 546547 547548 548549 549550 550551 551552 552553 553554 554555 555556 556557 557558 558559 559560 560561 561562 562563 563564 564565 565566 566567 567568 568569 569570 570571 571572 572573 573574 574575 575576 576577 577578 578579 579580 580581 581582 582583 583584 584585 585586 586587 587588 588589 589590 590591 591592 592593 593594 594595 595596 596597 597598 598599 599600 600601 601602 602603 603604 604605 605606 606607 607608 608609 609610 610611 611612 612613 613614 614615 615616 616617 617618 618619 619620 620621 621622 622623 623624 624625 625626 626627 627628 628629 629630 630631 631632 632633 633634 634635 635636 636637 637638 638639 639640 640641 641642 642643 643644 644645 645646 646647 647648 648649 649650 650651 651652 652653 653654 654655 655656 656657 657658 658659 659660 660661 661662 662663 663664 664665 665666 666667 667668 668669 669670 670671 671672 672673 673674 674675 675676 676677 677678 678679 679680 680681 681682 682683 683684 684685 685686 686687 687688 688689 689690 690691 691692 692693 693694 694695 695696 696697 697698 698699 699700 700701 701702 702703 703704 704705 705706 706707 707708 708709 709710 710711 711712 712713 713714 714715 715716 716717 717718 718719 719720 720721 721722 722723 723724 724725 725726 726727 727728 728729 729730 730731 731732 732733 733734 734735 735736 736737 737738 738739 739740 740741 741742 742743 743744 744745 745746 746747 747748 748749 749750 750751 751752 752753 753754 754755 755756 756757 757758 758759 759760 760761 761762 762763 763764 764765 765766 766767 767768 768769 769770 770771 771772 772773 773774 774775 775776 776777 777778 778779 779780 780781 781782 782783 783784 784785 785786 786787 787788 788789 789790 790791 791792 792793 793794 794795 795796 796797 797798 798799 799700 800701 801702 802703 803704 804705 805706 806707 807708 808709 809700 810701 811702 812703 813704 814705 815706 816707 817708 818709 819700 820701 821702 822703 823704 824705 825706 826707 827708 828709 829700 830701 831702 832703 833704 834705 835706 836707 837708 838709 839700 840701 841702 842703 843704 844705 845706 846707 847708 848709 849700 850701 851702 852703 853704 854705 855706 856707 857708 858709 859700 860701 861702 862703 863704 864705 865706 866707 867708 868709 869700 870701 871702 872703 873704 874705 875706 876707 877708 878709 879700 880701 881702 882703 883704 884705 885706 886707 887708 888709 889700 890701 891702 892703 893704 894705 895706 896707 897708 898709 899700 900701 901702 902703 903704 904705 905706 906707 907708 908709 909700 910701 911702 912703 913704 914705 915706 916707 917708 918709 919700 920701 921702 922703 923704 924705 925706 926707 927708 928709 929700 930701 931702 932703 933704 934705 935706 936707 937708 938709 939700 940701 941702 942703 943704 944705 945706 946707 947708 948709 949700 950701 951702 952703 953704 954705 955706 956707 957708 958709 959700 960701 961702 962703 963704 964705 965706 966707 967708 968709 969700 970701 971702 972703 973704 974705 975706 976707 977708 978709 979700 980701 981702 982703 983704 984705 985706 986707 987708 988709 989700 990701 991702 992703 993704 994705 995706 996707 997708 998709 999700 000701 001702 002703 003704 004705 005706 006707 007708 008709 009700 010701 011702 012703 013704 014705 015706 016707 017708 018709 019700 020701 021702 022703 023704 024705 025706 026707 027708 028709 029700 030701 031702 032703 033704 034705 035706 036707 037708 038709 039700 040701 041702 042703 043704 044705 045706 046707 047708 048709 049700 050701 051702 052703 053704 054705 055706 056707 057708 058709 059700 060701 061702 062703 063704 064705 065706 066707 067708 068709 069700 070701 071702 072703 073704 074705 075706 076707 077708 078709 079700 080701 081702 082703 083704 084705 085706 086707 087708 088709 089700 090701 091702 092703 093704 094705 095706 096707 097708 098709 099700 100701 101702 102703 103704 104705 105706 106707 107708 108709 109700 110701 111702 112703 113704 114705 115706 116707 117708 118709 119700 120701 121702 122703 123704 124705 125706 126707 127708 128709 129700 130701 131702 132703 133704 134705 135706 136707 137708 138709 139700 140701 141702 142703 143704 144705 145706 146707 147708 148709 149700 150701 151702 152703 153704 154705 155706 156707 157708 158709 159700 160701 161702 162703 163704 164705 165706 166707 167708 168709 169700 170701 171702 172703 173704 174705 175706 176707 177708 178709 179700 180701 181702 182703 183704 184705 185706 186707 187708 188709 189700 190701 191702 192703 193704 194705 195706 196707 197708 198709 199700 200701 201702 202703 203704 204705 205706 206707 207708 208709 209700 210701 211702 212703 213704 214705 215706 216707 217708 218709 219700 220701 221702 222703 223704 224705 225706 226707 227708 228709 229700 230701 231702 232703 233704 234705 235706 236707 237708 238709 239700 240701 241702 242703 243704 244705 245706 246707 247708 248709 249700 250701 251702 252703 253704 254705 255706 256707 257708 258709 259700 260701 261702 262703 263704 264705 265706 266707 267708 268709 269700 270701 271702 272703 273704 274705 275706 276707 277708 278709 279700 280701 281702 282703 283704 284705 285706 286707 287708 288709 289700 290701 291702 292703 293704 294705 295706 296707 297708 298709 299700 300701 301702 302703 303704 304705 305706 306707 307708 308709 309700 310701 311702 312703 313704 314705 315706 316707 317708 318709 319700 320701 321702 322703 323704 324705 325706 326707 327708 328709 329700 330701 331702 332703 333704 334705 335706 336707 337708 338709 339700 340701 341702 342703 343704 344705 345706 346707 347708 348709 349700 350701 351702 352703 353704 354705 355706 356707 357708 358709 359700 360701 361702 362703 363704 364705 365706 366707 367708 368709 369700 370701 371702 372703 373704 374705 375706 376707 377708 378709 379700 380701 381702 382703 383704 384705 385706 386707 387708 388709 389700 390701 391702 392703 393704 394705 395706 396707 397708 398709 399700 400701 401702 402703 403704 404705 405706 406707 407708 408709 409700 410701 411702 412703 413704 414705 415706 416707 417708 418709 419700 420701 421702 422703 423704 424705 425706 426707 427708 428709 429700 430701 4

2-TRIFLUOROACETYLAMINOMETHYL PIPERAZINE

To a solution of 3.1 g (6.7 mmol) of 2-trifluoroacetylaminomethyl-1,4-diphenylmethyl piperazine dihydrochloride in 100 ml methanol was added a suspension of 0.5 g palladium on carbon in 2 ml water.

5 The mixture was hydrogenized for 30 mn, the catalyst was filtered off and the solvent was removed, taken up in 10 ml absolute ethanol, evaporated again and crystallized in ether to yield 1.37 g of a white powder (72%) as title compound.

10 EXAMPLE G3-BENZYL-2,4-DIOXO-3,8-DIAZABICYCLO [3.2.1] OCTANE

In a dry flask were mixed 15 g of dry pyridine hydrochloride and 3.15 g (130 mmol) of 3-benzyl-2,4-dioxo-8-methyl-3,8-diazabicyclo [3.2.1] octane prepared according to U.S. Patent N° 3,328,398 in 1967, June 27. The mixture was heated in an oil bath preheated at 220°C for 20 mn, cooled in an ice-bath, dissolved in 90 ml water, extracted four times with 100 ml ethyl ether. The organic layers were collected and dried over magnesium sulfate. After removing the solvent, the residue was chromatographed over silica-gel using dichloromethane/ethylacetate (80:20) to afford 1.5 g of the title compound (50%). M.P. 72°C.

20

3-BENZYL-3,8-DIAZABICYCLO [3.2.1] OCTANE, DIHYDROCHLORIDE

In a dry flask were carefully placed 1.5 g (39.5 mmol) of lithium aluminum hydride to which were added 100 ml absolute ethyl ether. The suspension was flushed with nitrogen and cooled to 0°C. Then 1.7 g (7.4 mmol) of 3-benzyl-2,4-dioxo-3,8-diazabicyclo [3.2.1] octane was added portions wise for 15 mn. The mixture was heated under reflux for 3 hours, cooled, and washed up with water. The reaction mixture was filtered over a celite pad. The solvent was removed and the oily product was transformed as its dihydrochloride to yield 1.54 g (59%) of title compound. M.P. 158°C.

30

EXAMPLE H3-HYDROXY-4-AMINOCARBONYL-1-PHENYLMETHYL PYRROLIDINE

35

A solution of 11.0 g (44.0 mmol) of 3-hydroxy-4-ethyloxycarbonyl-1-phenylmethyl pyrrolidine (prepared according to E. JAEGER and J.H. BIEL in J. Org. Chem. 1965, 30, (740) in 40 g of 25% ammonia in methanol was heated at 100°C under pressure overnight. The solution was cooled and evaporated to dryness. The oily residue was purified by chromatography using dichloromethane-methanol (85:15) to yield 40 2.14 g (22%) of the title compound. M.P. 128°C.

3-HYDROXY-4-AMINOMETHYL-1-PHENYLMETHYL PYRROLIDINE

45 In a dry flask was place 1.34 g (35.0 mmol) of lithium aluminum hydride in 20 ml dry tetrahydrofuran cooled to -5°C. To this suspension was added dropwise 2.58 g (11.7 mmol) of 3-hydroxy-4-aminocarbonyl-1-phenylmethyl pyrrolidine. After completion of addition the suspension was warmed 2 hours under reflux, cooled. It was successively added 35 ml dichloromethane, 50 ml tetrahydrofuran and 2.3 ml water. The suspension was passed through a celite pad. The solvent removed to give 2.19 g (90.8%) of title compound 50 as an oil.

3-HYDROXY-4-AMINOMETHYL-PYRROLIDINE, DIHYDROCHLORIDE

55 A solution of 2.19 g (10.6 mmol) of 3-hydroxy-4-aminomethyl-1-phenylmethyl pyrrolidine in 60 ml anhydrous methanol and 5.3 ml 5N hydrochloric acid in ethanol was hydrogenized over 1.83 g palladium on carbon for 17 hours. The catalyst was filtered off, the solvent removed to afford 1.39 g (70%) of title compound.

PREPARATION OF QUINOLONE AND NAPHTHYRIDONE INTERMEDIATESEXAMPLE I5    3-(2,4-DICHLORO-5-FLUOROPHENYL)-3-OXO-2-(((1,1-DIMETHYLETHYL)AMINO)METHYLENE)-  
PROPANOIC ACID ETHYL ESTER

A solution of 0.95 mL of tert-butylamine (9 mmoles) in 2 mL of dry ethanol was added to 3.02 g (9 mmoles) of 3-(2,4-dichloro-5-fluorophenyl)-3-oxo-2-ethoxymethylene-propanoic acid ethyl ester in 10 mL of dry ethanol at -5°C.

10    The resulting mixture was stirred at room temperature for one hour. The resulting precipitate was collected by filtration and washed with 3 mL of ethanol and 5 mL of petroleum ether to afford 1.35 g of 3-(2,4-dichloro-5-fluorophenyl)-3-oxo-2-(((1,1-dimethylethyl)amino)methylene)-propanoic acid ethyl ester. MP 87°C.

15    The residual filtrate was evaporated to dryness. The resulting mixture (oil + solid) was crystallized in 3 mL of isopropanol to give 1.06 g more product. MP 88-89°C.

EXAMPLE II20    3-(2,3,4,5-TETRAFLUOROPHENYL)-3-OXO-2-(((1,1-DIMETHYLETHYL)AMINO)METHYLENE)-PROPANOIC  
ACID ETHYL ESTER

A solution of 1.77 g (24.2 mmoles) tert-butylamine in 2 mL ethanol was added to a mixture of 7.05 g (22 mmoles) of 3-(2,3,4,5-tetrafluorophenyl)-3-oxo-2-(ethoxymethylene)-propanoic acid ethyl ester and 9 mL 25 ethanol cooled in a bath containing ice and salt. More ethanol (2.3 mL) was added and the mixture was stirred at room temperature for 2 hours. After cooling at 0°C, the resulting precipitate was filtered and washed with ethanol to give 3.72 g of titled compound. MP 112°C.

30    EXAMPLE III3-(2,4,5-TRIFLUOROPHENYL)-3-OXO-2-(((1,1-DIMETHYLETHYL)-AMINO)-METHYLENE)-PROPANOIC  
ACID ETHYL ESTER

35    Tert-butylamine (6.2 mL, 84.7 mmoles) was added to a solution of 13.15 g (43.5 mmoles) of 3-(2,4,5-trifluorophenyl)-3-oxo-2-(ethoxymethylene)-propanoic acid ethyl ester in 19 mL of dry ethanol at -15°C. After 5 minutes, the mixture was stirred at room temperature for one hour, and then concentrated to dryness.

The crude residue (10.87 g) was crystallized from 25 mL of hexane to afford 7.22 g of titled compound.

40

EXAMPLE IV45    6,7,8-TRIFLUORO-1-(1,1-DIMETHYLETHYL)-1,4-DIHYDRO-4-OXO-3-QUINOLINE  
ETHYL ESTER      CARBOXYLIC      ACID

A mixture of 3.5 g (11 mmoles) of 3-(2,3,4,5-tetrafluorophenyl)-3-oxo-2-(((1,1-dimethylethyl)amino)methylene)-propanoic acid ethyl ester, 35mL dioxane and 0.512 g (12.7 mmoles) of 60% sodium hydride was stirred at room temperature under nitrogen for 6 hours and then at 40-50°C for one hour.

50    The dioxane was eliminated. The residue was taken up with cold water, the resulting solid was filtered and dried to give a mixture which was chromatographed over 200 g of silicagel using toluene-ethylacetate 80:20 as eluent. There was collected 1.54 g of titled compound. MP 146°C.

55    EXAMPLE V

6,7-DIFLUORO-1,4-DIHYDRO-1-(1,1-DIMETHYLETHYL)-4-OXO-3-QUINOLINE CARBOXYLIC ACID ETHYL ESTER

There was added 1.1 g (27 mmoles) of 60% sodium hydride portionwise, at a temperature between 5 18°C to 22°C, to a suspension of 7.22 g (21.9 mmoles) of 3-(2,4,5-trifluorophenyl)-3-oxo-2-((1,1-dimethylethyl)amino)methylene)propanoic acid ethyl ester in 73 mL of anhydrous dioxane. An exothermic reaction occurred. After stirring at room temperature during 1 hour, the resulting mixture was evaporated to dryness, and taken up with CH<sub>2</sub>Cl<sub>2</sub> (150 mL) and H<sub>2</sub>O (200 mL). After decantation the organic layer was dried over MgSO<sub>4</sub>. Evaporation of dichloromethane gave 6.41 g of an amorphous solid which was washed 10 twice with water to yield 6.08 g of titled compound.

EXAMPLE VI

75 6-FLUORO-7-CHLORO-(1,1-DIMETHYLETHYL)-1,4-DIHYDRO-4-OXO-3-QUINOLINE CARBOXYLIC ACID

To a solution of 3-(2,4-dichloro-5-fluoro)-3-oxo-2-((1,1-dimethyl ethyl)amino)methylene)propanoic acid ethyl ester in 10 mL dioxane at 7°C under nitrogen was added portionwise 0.34 g (8.45 mmoles) of 60% sodium hydride. During the addition 9mL more dioxane was added to help stirring. The final mixture was 20 stirred for 30 minutes at room temperature and then heated under reflux for 2.25 hours. The solvent was evaporated *in vacuo* to give the crude ethyl ester of the titled compound. To this product was added 10 mL of water and 0.6 g of potassium hydroxide. This mixture was heated under reflux for 1.5 hours, cooled to room temperature, acidified to pH 1-2 with 6N hydrochloric acid. The resulting precipitate was collected by filtration, washed with water, and recrystallized from water (3mL) + dioxane (60 mL) to give 0.8 g of 6-fluoro-25 7-chloro-(1,1-dimethylethyl)-1,4-dihydro-4-oxo-3-quinoline carboxylic acid. mp 274°C (dec). Evaporation of the mother liquor gave a residue which was taken up with 15 mL boiling dioxane. After cooling and filtration 0.4 g more of titled carboxylic acid was obtained. MP 272-273°C (dec).

30 EXAMPLE VII

6,7-DIFLUORO-1-(1,1-DIMETHYLETHYL)-1,4-DIHYDRO-4-OXO-3-QUINOLINE CARBOXYLIC ACID

A mixture of 6.08 g (19.7 mmoles) of 6,7-difluoro-1-(1,1-dimethylethyl)-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid ethyl ester and 19.7 mmoles of 2N aqueous sodium hydroxide in 80 mL of ethanol was stirred 35 overnight. The resulting mixture was concentrated in *vacuo*, taken up with 200 mL of water and extracted with dichloromethane. About 8 mL of 2N HCl was added to the aqueous layer to adjust the pH to 3. The precipitate was collected by filtration, washed with H<sub>2</sub>O and dried to give 4.47 g, of titled compound. MP > 260°C.

40.

EXAMPLE VIII

45 3-(2,6-DICHLORO-3-FLUORO-5-PYRIDINYL)-3-OXO-2-((1,1-DIMETHYLETHYL)AMINO)METHYLENE)-PROPAANOIC ACID ETHYL ESTER

A solution of 10.8 g (148 mmoles) of tert-butylamine in 50 mL dry ethanol was added dropwise in about 30 minutes to a suspension of 50 g (148 mmoles) of 3-(2,6-dichloro-3-fluoro-5-pyridinyl)-3-oxo-2-((1,1-dimethylethyl)amino)methylene)propanoic acid ethyl ester in 125 mL dry ethanol at -5°C under nitrogen. 50 The mixture was stirred at room temperature for one hour. The solvent was evaporated. The resulting oil (54.3 g) was stirred in 100 mL of petroleum ether for 0.5 hour with cooling. The precipitated yellow solid was filtered, washed with petroleum ether, and dried in *vacuo* over phosphorous pentoxide to afford 47.7 g of titled compound. MP 78°C.

55

EXAMPLE IX

7-FLUORO-6-CHLORO-1,4-DIHYDRO-1(1,1-DIMETHYLETHYL)-4-OXO-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID ETHYL ESTER

There was gradually added 1.3 g (32.4 mmoles) of 60% sodium hydride under nitrogen at room temperature to a solution of 10 g (27.5 mmoles) of 3-(2,6-dichloro-3-fluoro-5-pyridinyl)-3-oxo-2-((1,1-dimethylethyl)amino)methylene)propanoic acid ethyl ester (10 g) in 34 mL dry dioxane .3 mL. The temperature raised spontaneously to +60°C. After stirring for 15 minutes, the solvent was eliminated in vacuo. The resulting solid was taken up with 100 mL dichloromethane and the mixture was chilled in an ice bath. After decantation, the organic layer was washed with cold water and dried over magnesium sulfate to afford 8.2 g of title compound. MP 155°C. (A sample washed with hexane melted at 158°C).

EXAMPLE X

15 6-FLUORO-7-ETHYLTHIO-1,4-DIHYDRO-1-(1,1-DIMETHYLETHYL)-4-OXO-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID ETHYL ESTER

Acetone (90mL) was added to a mixture of 1.96 g (6 mmoles) of 6-fluoro-7-chloro-1-(1,1-dimethylethyl)-1,4-dihydro-4-oxo-1,8 naphthyridine-3-carboxylic acid ethyl ester and 2.5 g (18 mmoles) of anhydrous potassium carbonate. To this suspension was added 1.33 mL (18 mmoles) of ethanethiol. After heating to reflux for 2.5 hours, the solvent was eliminated in vacuo. The residue was taken up with ethylacetate and water. The organic layer was separated, washed with water and brine, and dried over magnesium sulfate. The resulting solid was treated with ether to give 1.67 g of titled compound. MP 159-60°C.

25 EXAMPLE XI

6-FLUORO-7-ETHYLTHIO-1,4-DIHYDRO-1-(1,1-DIMETHYLETHYL)-4-OXO-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID

A suspension of 0.23 g (0.65 mmoles) of 6-fluoro-7-ethylthio-(1,1-dimethylethyl)-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid ethyl ester in 1 mL of water was treated with 1.3 mL of 1N aqueous sodium hydroxide and the mixture was heated under reflux for 45 minutes. The resulting precipitate was acidified with 1 mL of 2N hydrochloric acid, filtered, washed with water and dried in vacuo at 50°C to give 0.196 g of titled compound. MP 215°C.

EXAMPLE XII

40 6-FLUORO-7-ETHYLSULFONYL-1-(1,1-DIMETHYLETHYL)-1,4-DIHYDRO-4-OXO-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID

A suspension of 1.34 g (4.1 mmoles) of 7-ethylthio-6-fluoro-1-(1,1-dimethylethyl)-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid in 20 mL acetic acid was cooled to +5°C. Then 2.5 mL 30% hydrogen peroxide was added dropwise. After the addition, the suspension was carefully warmed at 45°C until a clear solution was obtained. The mixture was held at room temperature for 48 hours. The precipitate was filtered and washed with water and ether to give 0.90 g of titled compound. MP 207°C. (dec).


The following Table 1 illustrates the quinoline-and naphthyridine-carboxylic acid antibacterial compounds described above in Examples 1-44 which are represented by the structural formula at the top of the table.

The compounds of this invention display antibacterial activity when tested by the microtitration dilution method reported by Heifetz et al., *Antimicr. Agents & Chemoth.*, 6, 124 (1974). Minimum inhibitory concentrations (MICs, in  $\mu$ g/ml) for but a few representative compounds according to this invention were determined by the above-mentioned method. The results are set forth in the following Table 2.

Quinoline analogs of Example 1 having 1,1-dimethylpropyl, 1-methylcyclopropyl, 1-methylcyclobutyl and isopropenyl substituents in the 1-position of the quinoline ring system were also prepared following substantially the procedures described herein. Representative quinolone compounds and naphthyridone compounds (generally as their methanesulfonate salts) were tested for in vitro biological activity, the results

of which are described for Table 2. All of these compounds gave results indicating antibacterial activity somewhat less than that given by the compound of Example 1 but still a useful level of antibacterial activity. Naphthyridine analogs of Example 1 (corresponding to Example 20 having the substituents in the 1-position of the naphthyridine ring system described above with regard to the quinoline analogs) are also specifically contemplated and are expected to show improvement in antibacterial activity over their quinoline analogs comparable to the improvement illustrated by Example 20 relative to Example 1.

TABLE 1 - LIST OF EXAMPLES



Ex.	<u>R<sup>1</sup></u>	<u>Y</u>	<u>Z</u>
1	C(CH <sub>3</sub> ) <sub>3</sub>	CH	1 - piperazinyl
2	"	"	4-(cyclopenten-3-yl)-1-piperazinyl
3	"	"	8-methyl-3,8-diazabicyclo[3.2.1]octan-3-yl
4	"	"	3-phenyl-1-piperazinyl
5	"	"	3-amino-3-methylpyrrolidin-1-yl
6	"	"	4-methyl-1-piperazinyl
7	"	"	2,5-diazabicyclo[2.2.2]octan-2-yl
8	"	"	1S,4S-2,5-diazabicyclo[2.2.1]heptan-2-yl
9	"	"	3-aminomethyl-1-pyrrolidinyl
10	"	"	3-(ethylamino)methyl-1-pyrrolidinyl
11	"	"	3-methyl-1-piperazinyl
12	"	"	3,5-dimethyl-1-piperazinyl
13	"	"	4-dimethylamino-1-piperazinyl
14	"	"	1R,4R-2,5-diazabicyclo[2.2.1]heptan-2-yl
15	"	"	4-(1,1-dimethylethyl)-1-piperazinyl
16	CF		1-piperazinyl
17	CF		3-(ethylamino)methyl-1-pyrrolidinyl
18	CF		1R,4R-2,5-diazabicyclo[2.2.1]heptan-2-yl
19	CH		3-amino-1-pyrrolidinyl
20	N		1-piperazinyl
21	"	"	3-methyl-1-piperazinyl
22	"	"	1S,4S-2,5-diazabicyclo[2.2.1]heptan-2-yl
23	"	"	2,5-diazabicyclo[2.2.2]octan-2-yl
24	"	"	4-(cyclopenten-3-yl)-1-piperazinyl
25	"	"	3-aminomethyl-1-pyrrolidinyl
26	"	"	3-(ethylamino)methyl-1-pyrrolidinyl
27	"	"	3-methyl-1-piperazinyl
28	"	"	3,4-dimethyl-1-piperazinyl
29	"	"	3-phenyl-1-piperazinyl
30	"	"	1R,4R-2,5-diazabicyclo[2.2.1]heptan-2-yl
31	"	"	1R,4R-5-methyl-2,5-diazabicyclo[2.2.1]-heptan-2-yl
32	"	"	8-methyl-3,8-diazabicyclo[3.2.1]octan-3-yl
33	"	"	3,8-diazabicyclo[3.2.1]octan-3-yl
34	"	"	2-aminomethyl-morpholin-4-yl
35	"	"	3-amino-3-methylpyrrolidin-1-yl
36	"	"	3-amino-1-pyrrolidinyl

20257 36490005

5


10

15

TABLE 1 - LIST OF EXAMPLES, CONTINUED

20

25



30

35

40

45

50

55

Ex.	<u>R<sup>1</sup></u>	<u>Y</u>	<u>Z</u>
37	C(CH <sub>3</sub> ) <sub>3</sub>	N	3-fluoromethyl-piperazin-4-yl
38	"	N	3-aminomethyl-piperazin-4-yl
39	"	CH	3-fluoromethyl-piperazin-4-yl
40	"	N	1,4-diazabicyclo[3.2.1]oct-4-yl
41	"	N	3,8-diazabicyclo[3.2.1]oct-8-yl
42	"	N	3-amino-4-methyl-1-pyrrolidinyl ( <u>cis</u> and <u>trans</u> mixture)
43	"	N	4-aminomethyl-3-hydroxy-1-pyrrolidinyl
44	"	CH	4-aminomethyl-3-hydroxy-1-pyrrolidinyl
45	"	N	(R)-3-amino-1-pyrrolidinyl
46	"	N	(S)-3-amino-1-pyrrolidinyl
47	"	N	<u>cis</u> -3-amino-4-methyl-1-pyrrolidinyl
48	"	N	<u>trans</u> -3-amino-4-methyl-1-pyrrolidinyl

TABLE 2 -- MIC (mg/ml)

<sup>10</sup> The following abbreviations are used in Table 2:

	Nal	= nalidixic acid
	Nor	= norfloxacin
<sup>15</sup>	Cip	= ciprofloxacin
	S. aur.	= <i>Staphylococcus aureus</i>
	S. faecal.	= <i>Streptococcus faecalis</i>
	S. faeci.	= <i>Streptococcus faecium</i>
	E. coli	= <i>Escherichia coli</i>
<sup>20</sup>	K. oxyto.	= <i>Klebsiella oxytoca</i>
	E. clo.	= <i>Enterobacter cloacae</i>
	P. aer.	= <i>Pseudomonas aeruginosa</i>

Ex.	S. aur.	S. faecal.	S. faeci.	E. coli	K. oxyto.	E. clo.	P. aer.
No.							
25	Nal.	8.0	>125	>125	2.0	63.0	72.0
	Nor.	0.25	1.0	8.0	0.13	0.25	0.5
	Cip.	0.06	0.5	4.00	0.016	0.03	0.06
30	1	0.03	0.13	2.0	0.03	2.0	0.06
	2	0.06	2.0	-	0.13	4.0	1.0
	6	0.03	0.5	-	0.016	0.5	0.25
	7	0.13	1.0	2.0	0.5	2.0	0.25
	8	0.25	4.0	16.0	0.5	2.0	0.5
35	9	0.03	0.25	0.5	0.5	2.0	0.25
	10	0.06	0.5	2.0	0.5	4.0	0.5
	11	0.06	1.0	4.0	0.06	0.06	0.03
	12	0.25	2.0	4.0	0.13	1.0	0.25
	13	0.13	2.0	4.0	0.13	2.0	0.25
40	14	0.5	2.0	2.0	0.25	2.0	0.25
	15	0.13	2.0	4.0	0.25	8.0	0.5
	16	0.25	8.0	16.0	0.06	1.0	0.25
	17	0.06	0.25	0.5	0.25	1.0	0.25
	20	0.06	0.5	4.0	0.016	0.5	0.06
45	21	0.06	2.0	4.0	0.03	0.25	0.06
	22	0.03	1.0	4.0	0.06	1.0	0.25
	23	0.03	0.5	2.0	0.13	0.5	0.06
	24	0.03	0.5	1.0	0.25	2.0	0.25
	25	0.03	0.25	0.5	0.25	1.0	0.5
50	26	0.13	2.0	8.0	0.25	1.0	0.25
	30	0.06	0.51	0.5	0.06	0.06	0.06
	32	0.25	2.0	4.0	0.5	2.0	0.25

TABLE 3 -- MIC (ug/ML)

The following abbreviations are used in Table 3:


Nor	= norfloxacin
Cip	= ciprofloxacin
S. aur.	= <i>Staphylococcus aureus</i>
S. faecal.	= <i>Streptococcus faecalis</i>
S. faecii.	= <i>Streptococcus faecium</i>
E. coli	= <i>Escherichia coli</i>
K. pneum.	= <i>Klebsiella pneumoniae</i>
E. clo.	= <i>Enterobacter cloaca</i>
P. aer.	= <i>Pseudomonas aeruginosa</i>

Ex. No.	S. aur.	S. faecal.	S. faeci.	E. coli.	K. pneum.	E. clo.	P. aer.
Cip.	0.13	0.5	8	0.015	0.03	0.008	0.13
Nor.	0.25	2	8	0.06	0.03	0.06	0.5
30	0.06	0.25	2	0.06	0.06	0.03	0.13
36	0.015	0.25	1	0.13	0.13	0.06	0.25
42	0.03	0.25	1	0.008	0.06	0.015	0.25
45	0.15	0.13	1	0.06	0.13	0.06	0.25
46	0.008	0.03	0.25	0.015	0.03	0.008	0.06
47	0.015	0.13	1	0.25	0.03	0.13	0.5
48	0.008	0.06	0.5	0.015	0.06	0.015	0.25

TABLE 4 - TOXICOLOGIC TEST RESULTS &amp; WATER SOLUBILITY

EX. NO.	LD50 mg/kg	LD0 mg/kg	WATER SOLUBILITY mg/ml (pH iso)
Cip.	N/A	N/A	0.07
30	N/A	N/A	0.08
46	350	N/A	0.01
47	>1000	>1000	0.03
48	>1000	>1000	0.24

The data set forth in Tables 2, 3 and 4 above show that the compounds described above as the most especially preferred, namely those compounds according to Formula I wherein R<sup>1</sup> is -C(CH<sub>3</sub>)<sub>2</sub>, X is F, Y is N, and Z is selected from



(racemic mixture, cis-isomer and trans-isomer), possess an especially advantageous broad spectrum of anti-bacterial activity. Among these compound, 7-(*trans*-3-amino-4-methyl-pyrrolidin-1-yl)-1-(1,1-dimethylethyl)-1,4-dihydro-8-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid (methanesulfonate) (Ex. 48) is the most especially preferred because it has been shown to possess the most advantageous combination of anti-bacterial, toxicity, and water-solubility properties. A compound as named above except having a 7-[(1R, 4R)-2,5-diazabicyclo[2.2.1]heptan-2-yl] group (Ex. 30) also possesses a highly advantageous combination of

the above mentioned properties.

EXAMPLE :

5 PREPARATION OF R-AND S-3-AMINO-PYRROLIDINE AND USE OF SAME TO PREPARE EXAMPLES 45 AND 46, RESPECTIVELY.

(S)-3-(4-METHYLSULFONYLOXY)-1-PHENYLMETHYL PYRROLIDINE

70 To a solution of 16.4 g (92.5 mmol) of (S)-3-hydroxy-1-phenylmethyl pyrrolidine (prepared according to KOJIMA, Y; TAKENAKA, T in J. Med. Chem. 1986, 29, 2504) in 164 ml pyridine cooled to +5°C was added 19.35 g (101.7 mmol) of 4-toluenesulfonylchloride. The mixture was stirred 48 hours at +10°C. The solvent was removed and the residue was purified by chromatography using dichloromethane/acetone (95:5) to yield 18.80 g (63%) of title compound - M.P. 68°C.  $[\alpha]_D^{20} = -30^\circ$  (c = 5, MeOH).

(R)-3-(4-METHYSULFONYLOXY)-1-PHENYLMETHYL PYRROLIDINE

20 This product was prepared as example above (starting from d-malic acid). M.P. 62°C  $[\alpha]_D^{20} = +31.2^\circ$  (c = 5, MeOH). Alternatively it was possible to prepare the (R) isomer from the (S) isomer by transforming (S)-3-(4-methylsulfonyloxy)-1-phenylmethyl pyrrolidine in (R)-3-acetoxy-1-phenylmethyl pyrrolidine with tetraethyl ammonium acetate in ethyl acetate ( $[\alpha]_D^{20} = +21.9^\circ$ , c = 5, MeOH) which was successively hydrolyzed with aqueous sodium hydroxide and tosylated again at +5°C in pyridine to give the title compound.

(R)-3-AZIDO-1-PHENYLMETHYL PYRROLIDINE

30 To a solution of 17.1 g (51.6 mmol) of (S)-3-(4-methylsulfonyloxy)-1-phenylmethyl pyrrolidine in 200 ml anhydrous dimethylformamide preheated to 60°C was added 33.5 g (516 mmol) of sodium azide. The mixture was stirred 7 hours to 60°C. Insoluble material was filtered off. The solvent was removed at 50°C under reduced pressure. The residue was dissolved in ethyl acetate, washed twice with water and dried over magnesium sulfate to yield 7.95 g (76.5%) of title compound as an oil.

35  $[\alpha]_D^{20} = -7.2^\circ$  (c = 5, MeOH) - IR (cm<sup>-1</sup>) : 2100.

(S)-3-AZIDO-1-PHENYLMETHYL PYRROLIDINE

40 The (S) isomer was basically prepared in the same way as the (R) isomer starting from the (R) tosyl pyrrolidine -  $[\alpha]_D^{20} = +6.9^\circ$  (c = 5, MeOH).

(R)-3-AMINO-PYRROLIDINE, DIHYDROCHLORIDE

45 To a solution of 7.05 g (34.8 mol) of (R)-3-azido-1-phenylmethyl pyrrolidine and 34.8 ml aqueous 1N hydrochloric acid in 245 ml ethanol was added 3.5 g of 10% palladium on carbon. The mixture was hydrogenized for 30 mn. It was added 3.5 g more of the catalyst and the mixture hydrogenized again for 2 hours. The catalyst was filtered over a celite pad. It was added 34.8 ml aqueous 1N hydrochloric acid to the filtrat, which was evaporated under reduced pressure. The residue was taken up three times with 70 ml ethanol and the solvent removed each time. The dihydrochloride crystallized in the minimum amount of ethanol to give 4.45 g (80.5%) of title compound.

$[\alpha]_D^{20} = -1.2^\circ$  (c = 5, 0.1N HCl).

(S)-3-AMINO-PYRROLIDINE, DIHYDROCHLORIDE

This compound was prepared exactly as described in the above procedure with the (S)-3-azido-1-phenylmethyl pyrrolidine.

5 [  $\alpha$  ]  $_{20}^D$  = +1° (c = 5; 0.1N HCl).

7-[(R)-3-AMINO-1-PYRROLIDINYL]-1-(1,1-DIMETHYLETHYL)-1,4-DIHYDRO-6-FLUORO-4-OXO-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID, ETHYL ESTER

10 To a suspension of 0.48 g (3.02 mmol) of (R)-3-amino-1-pyrrolidine, dihydrochloride and 0.76 g (2.30 mmol) of 1-(1,1-dimethylethyl)-1-1,4-dihydro-7-chloro-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid, ethyl ester in 15 ml acetonitrile was added 1.40 g (9.26 mmol) of 1,8-diazabicyclo[5.4.0]undec-7-ene. The solution was heated one hour at +65°C. The reaction mixture was cooled in an ice-bath. The precipitate was filtered and dried to yield 0.77 g (89.5%) of title compound - M.P. 257°C.

15 [  $\alpha$  ]  $_{20}^D$  = +73.5° (c = 2, 0.1N HCl/MeOH 50:50).

7-[(S)-3-AMINO-1-PYRROLIDINYL]-1-(1,1-DIMETHYLETHYL)-1,4-DIHYDRO-6-FLUORO-4-OXO-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID, ETHYL ESTER

20 The (S) isomer was prepared as described for (R) isomer as above. M.P. 257°C.

[  $\alpha$  ]  $_{20}^D$  = -8.1°.

7-[(R)-3-AMINO-PYRROLIDINYL]-1-(1,1-DIMETHYLETHYL)-1,4-DIHYDRO-6-FLUORO-4-OXO-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID, METHANESULFONATE

25 A suspension of 6.80 g (17.5 mmol) of 7-[(R)-3-amino-1-pyrrolidinyl]-1-(1,1-dimethylethyl)-1,4-dihydro-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid, ethyl ester in a solution of 70 ml 1N aqueous sodium hydroxide was heated under reflux for 20 mn. The solution was cooled and the pH was adjusted to 6.5 with 12N hydrochloric acid. The precipitate was filtered and dried to give 5.95 g of the amino-acid. M.P. 256°C, [  $\alpha$  ]  $_{20}^D$  = 24.4° (c = 1, 0.1N HCl). This amino-acid was suspended in 80 ml methanol and heated under reflux. To this hot suspension was added 1.28 ml (19.8 mmol) of methanesulfonic acid and then 100 ml of methanol in order to get a solution at reflux. The solution was concentrated to 100 ml and kept in a refrigerator for 30 mn. The precipitate was filtered and dried to give 5.9 g (75.9%) of title compound. M.P. 255°C;

30 [  $\alpha$  ]  $_{20}^D$  = -18.6° (c = 1, 0.1N HCl).

7-[(S)-3-AMINO-1-PYRROLIDINYL]-1-(1,1-DIMETHYL)-1,4-DIHYDRO-6-FLUORO-4-OXO-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID, METHANESULFONATE

35 This compound was prepared according to the procedure described above. M.P. 253-254°C.

40 [  $\alpha$  ]  $_{20}^D$  = +21.4° (c = 1, 0.1N HCl).

EXAMPLE -50 PREPARATION OF (1R, 4R)-2,5-DIAZABICYCLO-[2.2.1]-HEPTANE, DIHYDROBROMIDEALLO-4-HYDROXY-D-PROLINE HYDROCHLORIDE (1)

55 Ref: D.L. Baker, S.J. Fritschel, J.R. Stille and J.K. Stille, J. Org. Chem. (1981) Vol 46, pp. 2954-2960. [  $\alpha$  ]  $_{D}^b$  = + 19.81° (c = 2, H<sub>2</sub>O)

ALLO-4-HYDROXY-D-PROLINE ETHYL ESTER HYDROCHLORID (2)

A slurry of 240 g (1.432 mole) mor Allo-4-hydroxy-D-Proline hydrochloride in 1.2 L of absolute ethanol was treated with dry hydrogen chloride until homogeneous. The solution was heated to the reflux temperature for 5 h. The mixture was kept at room temperature overnight, then cooled in an ice bath and the resulting precipitate was filtered, washed with acetone and dried under reduced pressure to yield 212.1 g (75%) of (2) M.P. - 148°C.  
 $[\alpha]_D = +20.37^\circ$  (c = 2, H<sub>2</sub>O).

10 ALLO-1-(4-TOLUENESULFONYL)-4-(TOLUENESULFONYLOXY)-D-PROLINE ETHYL ESTER (3)

To a cold solution of 74 g (0.377 mole) of allo-4-hydroxy-D-proline Ethyl Ester Hydrochloride (2) and 38.1 g of triethylamine (0.377 mole) in pyridine (740 ml) at -5°C there was added portionwise 158.2 g (0.83 mole) of 4-toluenesulfonyl chloride. The cold solution was stirred 1 h at 0°C, stored overnight in the refrigerator. Then the mixture was stirred at room temperature for 5 h, poured into ice water (550 ml). The precipitate was filtered, washed with water, dried to give 131 g (74.2%) of the titled compound. M.P. = 125°C.  
 $[\alpha]_D = +26.48^\circ$  (c = 2, CHCl<sub>3</sub>)

20 4-(ACETYLOXY)-1-(4-TOLUENESULFOXYL)-D-PROLINE ETHYL ESTER (4)

To 350 ml of toluene were added 20 g (0.150 mole) of anhydrous tetramethylammonium acetate and 54.8 g (0.117 mole) of allo-1-(4-toluenesulfonyl)-4-(4-toluenesulfonyloxy)-D-proline ethyl ester (3) under nitrogen. The mixture was refluxed overnight and then cooled. The organic layer was washed with water (2 x 100 ml), dried over magnesium sulfate, filtered and evaporated to dryness. The residue (40 g) was taken up with 80 ml of isopropanol. The mixture was stirred for 30 minutes at 0°C, the resulting crystalline product was collected, dried under reduced pressure to give 30.3 g (74%) of the title compound. M.P. = 81°C.  
 $[\alpha]_D = +82.64^\circ$  (c = 2, CHCl<sub>3</sub>).

4-HYDROXY-1-(4-TOLUENESULFONYL)-D-PROLINE ETHYL ESTER (5)

35 To the suspension of 1665 g of compound (4) in 20 L of methanol there was added 8 L of distilled water. The pH was adjusted to 11-11.5 using sodium carbonate (~ 45 g). After 4 hours the pH was adjusted to 7 using acetic acid (~ 22.5 ml) and the mixture kept at room temperature overnight. At this time the pH was adjusted to 7 with another portion of acetic acid (2.5 ml), the solution volume was reduced by half by rotary evaporation. Then 20 L of water were added and the mixture was extracted with 2 portions of dichloromethane (15 L and 3 L). The combined extracts were washed with water (5 L), dried over magnesium sulfate, filtered and evaporated under reduced pressure to give 1444.4 g of an oily product (98%).  
 $[\alpha] = +100.35^\circ$  (c = 1.8, EtOH).  
K.F. - 0.78%

45

4-HYDROXY-1-(4-TOLUENESULFONYL)-D-PROLINOL (6)

To an ice-cold solution of 286.4 g (0.914 mole) of 4-hydroxy-(4-toluenesulfonyl)-D-proline ethyl ester (5) in 2.8 L of tetrahydrofuran was added 20 g (0.918 mole) of lithium borohydride in one portion. The mixture was stirred at 0°C for 1 hour and then kept at a temperature below 25°C overnight. The mixture was cooled to 0°C and the pH adjusted to 3 with 6N hydrochloric acid (180 ml). The volume was reduced to 500 ml by rotary evaporation, and 1.5 L of water was added. The white precipitate was filtered, washed with cold water (500 ml) dried under reduced pressure to give 223.8 g (90%) of the title compound. M.P. = 127°C.  
 $[\alpha]_D = 36.88^\circ$  (c = 1.0, acetone)  
K.F. - 6.55%

(2R, 4S)-1-(4-TOLUENESULFONYL)-2-(4-TOLUENESULFONYLOXYMETHYL)-4-(4-TOLUENESULFONYLOXY)-PYRROLIDINE (7)

To an ice-cold solution of 219.2 g (0.808 mole) of 2R, 4S-1-(4-toluenesulfonyl)-2-hydroxymethyl-4-hydroxy-pyrrolidine (6) in 1 L of pyridine were added 539.2 g (2.828 mole) of 4-toluenesulfonyl chloride in one portion. The temperature rose to 50°C. The mixture was cooled at 10°C and kept for 2 hours at this temperature and then at room temperature overnight. The mixture was pured into 5 L of 2.4 N hydrochloric acid. After cooling, a precipitate was collected, washed with cold water, dried under reduced pressure. This precipitate was taken up with 1 L of ethanol, filtered and washed with cold ethanol, dried under reduced pressure to give 406 g (86%) of the titled compound.

M.P. = 134°C.  
 $[\alpha]_D = +57.13^\circ$  (c = 1.9, acetone).

15 (1R, 4R)-2-(4-TOLUENESULFONYL)-5-PHENYLMETHYL-2,5-DIAZABICYCLO-[2.2.1]-HEPTANE (8)

A mixture of 2697 g (4.653 moles) of (2R, 4S)-1-(4-toluenesulfonyl)-2-(4-toluenesulfonyloxymethyl)-4-(4-toluenesulfonyloxy)-pyrrolidine and 1640 g (15.304 moles) of benzylamine in 15 L of toluene was heated under reflux. After 6 hours 100 g of benzylamine were added and the reflux continued for 3 hours. The mixture was cooled, filtered and the residue was washed with 5 L of toluene. The combined organic layers were evaporated to dryness and the resulting solid was taken up with 2 L of isopropanol. After cooling the product was filtered, washed with cold isopropanol and dried under reduced pressure to give 1434 g of the titled compound. (90%). M.P. = 124°C.  
 $[\alpha]_D = -15.72^\circ$  (c = 1.6, acetone)

26

(1R, 4R)-5-PHENYLMETHYL-2,5-DIAZABICYCLO-[2.2.1]-HEPTANE, DIHYDROBROMIDE (9)

To a hot solution of 2.85 L of hydrobromic acid 33% in acetic acid and 14 L of acetic acid, at 70°C there was added 1428 g (4.17 moles) of (1R, 4R)-2-(4-toluenesulfonyl)-5-phenylmethyl-2,5-diazabicyclo-[2.2.1]-heptane (8). The solution was stirred for 12 h. The resulting suspension was cooled (18-20°C). The precipitate was filtered, washed with diisopropylether and dried at 40°C under reduced pressure to give 1294 g (89%) of the titled compound. M.P. = 278°C.  
 $[\alpha]_D = -0.38^\circ$  (c = 1, H<sub>2</sub>O).

35

(1R, 4R)-2,5-DIAZABICYCLO-[2.2.1]-HEPTANE, DIHYDROBROMIDE (10)

A suspension of 76 g (0.217 moles) of (1R, 4R)-5-phenylmethyl-2,5-diazabicyclo-[2.2.1]-heptane, dihydribromide (9) and 37 g of 10% Pd on C in 1.2 L of water was hydrogenated at atmospheric pressure at 40°C. The reaction was completed within 8 hours. The catalyst was filtered off and the filtrate was evaporated under reduced pressure. The residue was taken up with ethanol and the resulting precipitate was filtered to give 51.4 g (91%) of the titled compound. M.P. = 285°.  $[\alpha]_D = -19.83$  (c = 1.2, 0.1N HCl).

45

3(R)-N,N'-DIMETHYLHYDRAZINO-1-PHENYLMETHYL PYRROLIDINE, 4-METHYLPHENYLSULFONIC ACID SALT

To a solution of 3.96 g (12 mmoles) of 3(S)-(4-methylphenylsulfonyloxy)-1-phenylmethyl pyrrolidine in 40 mL anhydrous methanol was added 2.15 g (36 mmoles) of N,N-dimethylhydrazine. The solution was heated under reflux for 9 hours. Then, the solvent was evaporated. The residue was taken up with dichloromethane and brine, the organic layer was dried over MgSO<sub>4</sub> to give 2.4 g of crude product which was recrystallized in ethyl acetate to afford 1.61 g of title compound. Yield 36%.

55

### 3(R)-N',N'-DIMETHYLHYDRAZINO-PYRROLIDINE, DIHYDROCHLORIDE

5 A suspension of 0.82 g (2.1 mmoles) of 3(R)-N,N'-dimethylhydrazino-1-phenylmethyl pyrrolidine, 4-methylphenylsulfonic acid salt and 700 mg Pd 10% on C in 20 mL ethanol was hydrogenolyzed at atmospheric pressure for one hour. The catalyst was filtered off and the solvent was evaporated from the filtrate, and the residue was taken up in 4 mL isopropanol to which was added 750 mL of 5N hydrochloric acid in ethanol. The precipitate was filtered to give 440mg of title compound. Yield 97%.

10 7-[3(R)-N,N'-DIMETHYLHYDRAZINO-PYRROLIDIN-1-YL]-1-(1,1-DIMETHYLETHYL)-6-FLUORO-1,4-DIHYDRO-4-OXO-1,8-MAPHTYRIDINE-3-CARBOXYLIC ACID, DIHYDROCHLORIDE

This compound was prepared essentially as described in example 30. Yield 76.7%. M.P. > 270°C;  
 $[\alpha]_D^{20} = -14.97^\circ$  (c = 0.2, H<sub>2</sub>O)

### 3(R)-[4-METHYLPIPERAZINYL]-1-PHENYLMETHYL PYRROLIDINE, DIHYDROCHLORIDE

To a solution of 3.31 g (10 mmoles) of 3(S)-4-methylphenylsulfonyloxy-1-phenylmethyl pyrrolidine in 13 mL anhydrous methanol was added 2.0 g (20 mmoles) of N-methylpiperazine. The solution was heated under reflux overnight. After evaporation of solvent the residue was taken up in 20 mL anhydrous ether. Insoluble material was filtered off and the filtrate evaporated to give 1.68 g of an oil which was transformed into his dichlorhydrinate in isopropanol with ethanolic hydrochloric acid to yield 1.25 g of title compound. M.P. 279-80°C dec. Yield 38%.

[ $\alpha$ ]  $_{20}^D$  = 1.76° (c = 5, MeOH).

## 3(R)-[4-METHYLPIPERAZIN-1-YL]-PYRROLIDINE, DIHYDROCHLORIDE

30 A suspension of 1.55 g (0.46 mmole) of 3(R)-[4-methyl(piperazin-1-yl)-1-phenylmethyle pynolidine, dihydrochloride and 0.48 g 10% Pd on C in 20 mL water was hydrogenolyzed at atmospheric pressure. The reaction was complete in about 4 hours. The catalyst was filtered off and the solvent was evaporated from the filtrate and the residue was triturated in ethanol to give 0.85 g (Yield 75%) of the title compound.

35 7-[3(R)-(4-METHYLPIPERAZIN-1-YL)-PYRROLIDINYL]-1-(1,1-DIMETHYL ETHYL)-6-FLUORO-1,4-DIHYDRO-4-OXO-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID, HYDROCHLORIDE, MONOHYDRATE

This compound was prepared basically as described in example 30. Yield 65%; M.P. 259-60°C;  
 40  $[\alpha]_D^{20} = 14.3^\circ$  (c = 0.2%, H<sub>2</sub>O).

**EXAMPLE -**

45 SYNTHESIS OF 7-PIPERAZINYL-6-FLUORO-1,4-DIHYDRO-1-(1-METHYLETHENYL)-4-OXO-1,8-NAPHTHYRIDINE CARBOXYLIC ACID:

**3-(2,6-DICHLORO-3-FLUORO-5-PYRIDINYL-3-OXO-2-((2-PHENYLTHIO-1-MEHYLETHYL)AMINO)-METHYLENE)-PROPANOIC ACID ETHYLESTER**

50 2.09 g (12.5 mmoles) of 2-amino-1-benzenethiopropane was added to a suspension of 4 g (12 mmoles) of 3-(2,6-dichloro-3-fluoro-5-pyridinyl)-3-oxo-2-ethoxymethylene-propanoic acid ethylester in 10 ml dry ethanol at -8° under nitrogen.

The mixture was stirred at room temperature for two and half hours. The precipitated product was filtered, washed with EtOH, dried in vacuo to afford 3.93 g of titled compound. MP 69–70°C.

7-FLUORO-6-CHLORO-1,4-DIHYDRO-1-(2-PHENYLTHIO-1-METHYLETHYL)-4-OXO-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID ETHYLESTER

5. There was gradually added 0.4 g (10 mmoles) of 60% NaH under nitrogen to a solution of 3.92 g (8.55 mmoles) of 3-(2,6-dichloro-3-fluoro-5-pyridyl)-3-oxo-2-((2-phenylthio-1-methylethyl) amino) methylene-propanoic acid ethylester with external cooling to keep the temperature below 40°C. After stirring for 25 min. at room temperature, the solvent was eliminated in vacuo.

10. The resulting mixture was taken up with 50 ml dichloromethane and 10 g ice. After decantation, inorganic layer was extracted with dichloromethane (3 x 10 ml). The collected organic layer was washed with water (10 ml) and dried over magnesium sulfate to afford 3.5 g of a product which was triturated with 50 ml of diisopropyloxide to give 2.75 g of titled compound. MP 70°C.

15. 7-FLUORO-6-CHLORO-1,4-DIHYDRO-1-(2-PHENYLSULFINYL-1-METHYLETHYL)-4-OXO-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID ETHYLESTER

There was gradually added 1.03 g (6 mmoles) of metachloroperbenzoic acid to a solution of 2.88 g (5.25 mmoles) of 7-fluoro-6-chloro-1,4-dihydro-1-(2-phenylthio-1-methylethyl)-4-oxo-1,8-naphthyridine-3-carboxylic acid ethylester at 5°C.

20. After stirring for 30 min. at room temperature, 25 ml of 10% sodium-bicarbonate was added. The aqueous phase was extracted with dichloromethane (2 X 10 ml). The collected organic phases were washed with water, dried over magnesium sulfate.

The residue (2.26 g) was chromatographed over silica gel using ethylacetate as eluant to give 1.5 g of titled compound. MP 170-2°C.

25

7-PIPERAZINYL-6-FLUORO-1,4-DIHYDRO-1-(2-PHENYLSULFINYL-1-METHYLETHYL)-4-OXO-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID ETHYLESTER

30. To a suspension of 2.47 g (5.65 mmoles) of 7-chloro-6-fluoro-1,4-dihydro-1-(2-phenylsulfinyl-1-methylethyl)-4-oxo-1,8-naphthyridine-3-carboxylic acid ethylester in 70 ml acetonitrile was added 1.95 g (22.6 mmoles) piperazine and the resulting mixture was stirred for one and half hours at room temperature.

35. After evaporation to dryness, the residue was taken up with water, extracted with dichloromethane (3 X 40 ml). This organic phase was washed with 15 ml water, dried over magnesiumsulfate. Evaporation of dichloromethane gave 2.66 g of a product which was triturated 50 ml ethylether to yield 2.46 g of titled compound. The purity was checked by tlc (methanol-dichloromethane 20/80).

40. 7-PIPERAZINYL-6-FLUORO-1,4-DIHYDRO-1-(1-METHYLETHENYL)-4-OXO-1,8-NAPHTHYRIDINE CARBOXYLIC ACID

A mixture of 0.63 g (1.58 mmoles) of 7-piperazinyl-6-fluoro-1,4-dihydro-1-(1-methylethethyl)-4-oxo-1,8-naphthyridine carboxylic acid ethylester hydrochloride and 4 ml 2N sodium hydroxyde was heated under reflux for 1 hr 40 min.

45. After cooling, the pH was adjusted to 7.3 with 2N hydrochloric acid. The precipitated solid was filtered, washed with water, taken up with 10 ml boiling methanol, cooled and filtered again. This filtered compound was recrystallized in 15 mL dimethylformamid-water 10:5 to yield 0.18 g of titled compound. MP 234°C.

50. EXAMPLE -

SYNTHESIS OF 7-PIPERAZINYL-6-FLUORO-1,4-DIHYDRO-4-OXO-1-(1-METHYLETHENYL)-3-QUINOLINECARBOXYLIC ACID

55

3-(2,4-DICHLORO-5-FLUOROPHENYL)-3-OXO-2-((2-DIMETHYLAMINO-1-METHYLETHYL)-METHYLENE)-PROPANOIC ACID ETHYLESTER AMINO)

6 A solution of 1.29 ml (10 mmoles) of 1-methyl-1-(dimethylamino)ethylamine in 5 mL ethanol was added during 10 min. to a solution of 3.35 g (10 mmoles of 3-(2,4-dichloro-5-fluorophenyl)-3-oxo-2-(ethoxymethylene)-propanoic acid ethylester in 10 mL ethanol at -8°C.

7 After stirring for 2 hr 30 min. at room temperature the mixture was evaporated to dryness to give 3.98 g of the titled compound as an oil.

10 7-CHLORO-6-FLUORO-1,4-DIHYDRO-1-(2-(DIMETHYLAMINO)-1-METHYLETHYL)-4-OXO-3-QUINOLINE CARBOXYLIC ACID ETHYLESTER

15 To a solution of 10 mmoles of 3-(2,4 dichloro-5-fluorophenyl)-3-oxo-2-((2-(dimethylamino)-1-methylethyl) amino) methylene)-propanoic acid ethylester in 40 ml dioxane was added 0.5 g (12 mmoles of 60% NaH in one portion.

20 The mixture was heated under reflux for two hours, evaporated to dryness and taken up with diethylether and water. The organic layer gave 3.3g crude product which was dissolved in 29 ml acetone. To this solution was added an excess of 5N ethanolic hydrochloric acid. The resulting hydrochloride was filtered and washed with acetone.

25 1.77 g of this hydrochloride was dissolved in 35 ml water and sodium hydroxyde was added to obtain pH > 11. After saturating with sodium hydrochloride, this solution was extracted with diethylether. The solvent was evaporated to dryness to afford 1.22 g titled compound (amorphous solid).

25 7-CHLORO-6-FLUORO-1,4-DIHYDRO-1-(2-(DIMETHYLAMINO)-1-METHYLETHYL)-4-OXO-3-QUINOLINE CARBOXYLIC ACID

30 A suspension of 1.8 mmoles of 7-chloro-6-fluoro-1,4-dihydro-1-(2-dimethylamino)-1-methylethyl)-4-oxo-3-quinoline carboxylic acid ethylester in 2.5 mL N NaOH was heated under reflux for 2 hours.

35 After cooling, the mixture was washed with ethylacetate (2 X 2 mL) and pH was adjusted to 6-6.5 with hydrochloric acid. The precipitated compound was filtered, washed with 2 mL water, 2 mL ethylacetate, 2 X 5 mL petroleum ether to give 0.31 g titled compound. MP 238°C.

35 N,N,N-TRIMETHYL-2-(3-(ETHOXYCARBONYL)-7-CHLORO-6-FLUORO-4-OXO-1,4-DIHYDRO-1-QUINOLEINYL)-PROPANAMINIUM IODINE

40 To a solution of 1.2 g (3.35 mmole) of 7-chloro-6-fluoro-1,4-dihydro-1-(2-(dimethylamino)-1-methylethyl)-4-oxo-3-quinolinecarboxylic acid ethylester in 10 mL acetone was added 2.1 mL (33.5 mmoles) of methyliodide. The mixture was stirred for 5 hours at room temperature and 5 ml diethylether was added to help the precipitation.

45 The precipitate was filtered and washed with diethylether to give 1.80 g titled compound. MP 210°C.

45 7-CHLORO-6-FLUORO-1,4-DIHYDRO-4-OXO-1-(1-METHYLETHENYL)-3-QUINOLINE CARBOXYLIC ACID METHYLESTER

50 A hot solution of 2.4 g of N,N,N-trimethyl-2-(3-ethoxycarbonyl)-7-chloro-6-fluoro-4-oxo-1,4-dihydro-1-quinoleinyl)-propanaminium iodide in 75 mL methanol was treated twice with Dowex 1 (OH form) (prepared from 9.6 g Dowex 1 (Cl form)). The resin was washed with 30 ml methanol. The methanol was evaporated in vacuo and the residue was treated for one hour at 190°C in vacuo.

55 The resulting product was chromatographed over silicagel using chloroform-methanol 97:3. The crude methylester was triturated in boiling diisopropylether. After cooling the solvent was eliminated by filtration to yield 0.3 g titled compound. RF = 0.41 (chloroform-methanol 97:3).

202207-06490005

7-CHLORO-6-FLUORO-1,4-DIHYDRO-4-OXO-1-(1-METHYLETHENYL)-3-QUINOLINE CARBOXYLIC ACID

5 A mixture of 0.3 g (1.07 mmoles) of 7-chloro-6-fluoro-1,4-dihydro-4-oxo-1-(1-methylethenyl)-3-quinoline carboxylic acid methylester, 1 mL methanol and 2.14 mL (2.14 mmoles) of normal sodium hydroxide was heated under reflux for one and half hours. More sodium hydroxide (1 ml) was added and the heat was continued for 30 min.

The solution was diluted with 2 mL water, acified with 6N hydrochloric acid, saturated with sodium chloride, extracted with ethylacetate and dried over magnesium sulfate to give 0.25 titled compound. MP 229°C.

10

6-FLUORO-1,4-DIHYDRO-7-PIPERAZINYL-4-OXO-1-(1-METHYLETHENYL)-3-QUINOLINE CARBOXYLIC ACID


15 A mixture of 0.25 g (0.89 mmmole) of 7-chloro-6-fluoro-1,4-dihydro-1-(1-methylethenyl)-4-oxo-3-quinoline carboxylic acid, 0.38 g (4.45 mmoles) of piperazine and 2.1 mL N-Methylpyrrolidine was heated at 100°C for 3 hours 30 min.

The final cooled mixture was diluted with 16 mL diethylether. The precipitated product was crystallized in 3.5 mL methanol to give 0.17 g titled compound. RF = 0.3. (Methanol - chloroform - ammoniac 4:6:1).

20 The following shows additional compounds within the scope of the invention. TABLE 5 which may be prepared, by following substantially the procedure described in Example 30 except for substituting varying amino reactants for that used in Example 30. The symbol \*\*\* designates compounds that have been prepared.

25


30

TABLE 5 - LIST OF ADDITIONAL EXAMPLES

40 Ex.	$\frac{R^1}{C(CH_3)_3}$	$\frac{Y}{N}$	$\frac{R^1}{R^2}$	3-aminomethyl-4-fluoro-1-pyrrolidinyl (cis & trans)
49	"	N		3-aminomethyl-4-fluoro-1-pyrrolidinyl (cis & trans)
50*	"	N		3-aminomethyl-4-fluoro-1-pyrrolidinyl (cis)
45 51*	"	N		3-aminomethyl-4-fluoro-1-pyrrolidinyl (trans)
52	"	N		3-amino-4-fluoro-1-pyrrolidinyl (cis & trans)
53	"	N		3-amino-4-fluoro-1-pyrrolidinyl (cis)
54	"	N		3-amino-4-fluoro-1-pyrrolidinyl (trans)
50 55*	"	N		3-methylamino-1-pyrrolidinyl

55

TABLE 5 - LIST OF ADDITIONAL EXAMPLES, CON'T.




Ex.	R <sup>1</sup>	Y	Z
56*	C(CH <sub>3</sub> ) <sub>3</sub>	N	3-ethylamino-1-pyrrolidinyl
57*	"	N	3-dimethylamino-1-pyrrolidinyl
58*	"	N	3-(R)-(4-methylpiperazin-1-yl)-1-pyrrolidinyl
59*	"	N	3-(R)-N',N'-dimethylhydrazino-pyrrolidin-1-yl
60	"	N	3-(iminomethyl)amino-1-pyrrolidinyl
61*	"	N	3-imino-1-pyrrolidinyl
62	"	N	3-(aminoiminomethyl)amino-pyrrolidinyl
63	"	N	2-methyl-4-amino-1-pyrrolidinyl (cis & trans)
64	"	N	2-methyl-4-amino-1-pyrrolidinyl (cis)
65	"	N	2-methyl-4-amino-1-pyrrolidinyl (trans)
66	"	N	3-hydroxyamino-1-pyrrolidinyl
67	"	N	3-hydroxyimino-1-pyrrolidinyl
68	"	N	3-(N-cyano)amino-1-pyrrolidinyl
69	"	N	2,6-diazabicyclo[3.2.0]heptan-6-yl
70	"	N	2-methyl-2,6-diazabicyclo[3.2.0]heptan-6-yl
71	"	N	3-(R)-amino-4-(R)-ethyl-1-pyrrolidinyl
72	"	N	3-(R)-amino-4-(S)-ethyl-1-pyrrolidinyl
73	"	N	3-(S)-amino-4-(R)-ethyl-1-pyrrolidinyl
74	"	N	3-(S)-amino-4-(S)-ethyl-1-pyrrolidinyl
75	"	N	2-(R)-methyl-3-(R)-amino-1-pyrrolidinyl
76	"	N	2-(R)-methyl-3-(S)-amino-1-pyrrolidinyl
77	"	N	2-(S)-methyl-3-(R)-amino-1-pyrrolidinyl
78	"	N	2-(S)-methyl-3-(S)-amino-1-pyrrolidinyl
79	"	N	3-(R)-amino-4-(R)-phenyl-1-pyrrolidinyl
80	"	N	3-(R)-amino-4-(S)-phenyl-1-pyrrolidinyl
81	"	N	3-(S)-amino-4-(R)-phenyl-1-pyrrolidinyl
82	"	N	3-(S)-amino-4-(S)-phenyl-1-pyrrolidinyl
83	C(CH <sub>3</sub> ) <sub>2</sub> CH <sub>2</sub> F	N	3-(S)-amino-1-pyrrolidinyl
84	"	N	trans-3-aminomethyl-4-fluoro-1-pyrrolidinyl
85	"	N	trans-3-amino-4-methyl-1-pyrrolidinyl
86	-C(CH <sub>3</sub> )CH <sub>2</sub> CH <sub>2</sub>	N	1-piperazinyl
87	-C(CH <sub>3</sub> )CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub>	N	1-piperazinyl

## Claims


1. A compound having the formula

5


10




wherein:

15 R<sup>1</sup> is a tertiary alkyl group selected from -C(CH<sub>3</sub>)<sub>3</sub>, -C(CH<sub>3</sub>)<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, -C(C<sub>6</sub>H<sub>5</sub>)(CH<sub>3</sub>)<sub>2</sub>,

20

25 -C(CH<sub>3</sub>)=CH<sub>2</sub>, and


30




35 wherein R is H or CH<sub>3</sub> and wherein the t-alkyl group may contain 1-3 halo groups;  
 X is a member of the group of halogen groups selected from F, Cl and Br and trihaloalkyl groups selected from CF<sub>3</sub> and CCl<sub>3</sub>;  
 Y is selected from CH, CF, CCl, CBr, and N; and  
 Z is selected from

40





45





50



55





wherein R<sup>2</sup> is independently selected from H, unsubstituted and substituted alkyl having 1 to 6 carbon atoms wherein the substituent is independently selected from 1-3 hydroxy, fluoro, chloro, amino, alkylamino, trifluoroacetyl amino, and phenyl groups; cycloalkyl having 3 to 6 carbon atoms, and cycloalkenyl having 3 to 6 carbon atoms; and wherein A, B, C, and D, are independently selected from H; unsubstituted and substituted lower alkyl having 1 to 4 carbon atoms wherein the substituent is independently selected from 1-3 hydroxy, fluoro, chloro, amino, alkylamino, trifluoroacetyl amino, and phenyl groups; amino; hydroxy; fluoro; chloro; and phenyl groups; and wherein n is selected from the integers 0, 1, 2, and 3, and wherein when the moiety R<sub>2</sub>N is present and each of the R<sup>2</sup> is other than H, the R<sup>2</sup> group is independently selected from CH<sub>3</sub> and C<sub>2</sub>H<sub>5</sub>;




and pharmaceutically acceptable acid addition and base salts thereof.


2. A compound according to Claim 1 wherein X is F.
3. A compound according to Claim 1 wherein Y is selected from CH, CF and N.
4. A compound according to Claim 1 wherein Z is selected from



10



5. A compound according to Claim 1 wherein R<sup>1</sup> is unsubstituted or substituted -C(CH<sub>3</sub>)<sub>3</sub>, -C(CH<sub>3</sub>)<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>.




25

and -C(CH<sub>3</sub>) = CH<sub>2</sub>.

6. A compound according to Claim 1 wherein  
R<sup>1</sup> is unsubstituted or substituted -C(CH<sub>3</sub>)<sub>3</sub>, -C(CH<sub>3</sub>)<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>.

30





35

and -C(CH<sub>3</sub>) = CH<sub>2</sub>;

X is F;


Y is selected from CH, CF, and N; and  
Z is selected from

40



45

50



wherein R<sup>2</sup> is independently selected from H, CH<sub>3</sub>, C<sub>2</sub>H<sub>5</sub>, -C(CH<sub>3</sub>)<sub>3</sub>, and



5; A, B, C, and D are independently selected from H, CH<sub>3</sub> and C<sub>2</sub>H<sub>5</sub>; and n is selected from 0, 1, and 2.




7. A compound according to Claim 6 wherein

R<sup>1</sup> is selected from -C(CH<sub>3</sub>)<sub>3</sub>, -C(CH<sub>2</sub>F)(CH<sub>3</sub>)<sub>2</sub>, -C(CH<sub>2</sub>F)<sub>2</sub>CH<sub>3</sub>, AND -C(CF<sub>3</sub>)(CH<sub>3</sub>)<sub>2</sub>;

Y is selected from CH and N; and

Z is selected from

10



20

8. A compound according to Claim 7 wherein R<sup>1</sup> is -CH(CH<sub>3</sub>)<sub>3</sub> and Y is CH.

9. A compound according to Claim 7 wherein R<sup>1</sup> is -C(CH<sub>3</sub>)<sub>3</sub> and Y is N.

10. A compound according to Claim 8 wherein Z is selected from

25



11. A compound according to Claim 10 wherein Z is

30



35


12. A compound according to Claim 10 wherein Z is



40


13. A compound according to Claim 9 wherein Z is selected from

45




50

(R<sup>2</sup> = H, CH<sub>3</sub>) and




55

14. A compound according to Claim 13 wherein Z is




5 15. A compound according to Claim 13 wherein Z is



10

16. A compound according to Claim 13 wherein Z is


15



20


17. A compound according to claim 16 wherein Z is

25



30


18. A compound according to Claim 13 wherein Z is



35

19. A compound according to claim 13 wherein Z is

40



45

20. A compound according to claim 19 wherein Z is



50

21. A pharmaceutical composition comprising an antibacterially effective amount of a compound according to Claim 1 and a pharmaceutically acceptable carrier.

22. A composition according to Claim 21 wherein the antibacterially effective amount of said compound comprises from about 0.5% to about 90% by weight of the composition.


23. A composition according to Claim 21 or 22 providing an antibacterially effective amount of said compound of about 0.1 to about 15 mg/kg of body weight/day.

24. A composition according to anyone of claims 21 to 23 comprising an antibacterially effective amount of a compound according to claim 13.

25. A composition according to anyone of claims 21 to 23 comprising an antibacterially effective amount of a compound according to claim 20.

26. A compound having the formula:


5




10

wherein: R<sup>1</sup> is a tertiary alkyl group selected from -C(CH<sub>3</sub>)<sub>3</sub>, -C(CH<sub>3</sub>)<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, -C(C<sub>6</sub>H<sub>5</sub>)(CH<sub>3</sub>)<sub>2</sub>,

10




15



-C(CH<sub>3</sub>)=CH<sub>2</sub>, and

20



25

wherein R is H or CH<sub>3</sub>;

X is a member of the group of halogen groups selected from F, Cl, and Br and trihaloalkyl groups selected from CF<sub>3</sub> and CCl<sub>3</sub>;

Y is selected from CH, CF, CCl, CBr and N; and

M is selected from H, C<sub>1</sub>-C<sub>4</sub> alkyl and alkali and alkaline earth metal ions.

30

27. A compound according to Claim 26 wherein

35

R<sup>1</sup> is -C(CH<sub>3</sub>)<sub>3</sub>;

X is selected from F and Cl;


Y is selected from CH, CF, and N.

28. A compound represented by the formula


Z-H (Formula III)

40

wherein Z is selected from



45



50

and the free amine hydrolysis product thereof, and

55





Europäisches Patentamt  
European Patent Office  
Office européen des brevets

⑪ Publication number:

0 266 576  
A3

⑫

## EUROPEAN PATENT APPLICATION

⑬ Application number: 87114686.6

⑭ Date of filing: 08.10.87

⑬ Int. Cl.4: C07D 215/56, C07D 401/04,  
C07D 471/04, C07D 471/08,  
C07D 519/00, A61K 31/47,  
A61K 31/435, A61K 31/495,  
//(C07D471/04,221:00,221:00),  
(C07D471/08,221:00,221:00),  
(C07D487/08,241:00,209:00),  
(C07D487/08,209:00,209:00),  
(C07D519/00,487:00,471:00)

⑬ Priority: 08.10.86 US 916752  
25.09.87 US 99231

⑬ Date of publication of application:  
11.05.88 Bulletin 88/19

⑬ Designated Contracting States:  
ES GR

⑬ Date of deferred publication of the search report:  
22.03.89 Bulletin 89/12

⑭ Applicant: Bristol-Myers Company  
345 Park Avenue  
New York New York 10154(US)

⑭ Inventor: Di Cesare, Pierre  
53, Rue Rene Bazin  
F-77100 Meaux(FR)  
Inventor: Jacquet, Jean-Pierre  
Chemin de St-Thibault  
F-45240 Menestreau-en-Villette(FR)  
Inventor: Essiz, Munir  
4 Mail F.Carcia Lorca  
F-93160 Noisy Le Grand(FR)  
Inventor: Remuzon, Philippe  
25, Rue de Crimée  
F-75019 Paris(FR)  
Inventor: Bouzard, Daniel  
11 Rue Amiat  
F-95130 Franconville(FR)  
Inventor: Weber, Abraham  
4 Avenue Herbillon  
F-94160 Saint-Mande(FR)

⑭ Representative: Kinzebach, Werner, Dr.  
Patentanwälte Reitstötter, Kinzebach und  
Partner Sternwartstrasse 4 Postfach 86 06 49  
D-8000 München 86(DE)

0 266 576 A3

⑬ 1-Tert-alkyl-substituted naphthyridine and quinoline carboxylic acids as antibacterial agents.

EP 0

⑬ There are disclosed new naphthyridine-and  
quinoline-carboxylic acids having a 1-tertiary-alkyl  
substituent, compositions containing them, and their  
use in treating bacterial infections in warm-blooded

animals. Also disclosed are novel amines and inter-  
mediates used in the preparation of the  
naphthyridine- and quinoline-carboxylic acids.



DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.4)
X	DE-A-3 509 546 (BAYER) * Claims 1-4, page 53, line 21 - page 55, line 19; page 64, line 25 - page 68, line 29 * --	1-7,21	C 07 D 215/56 C 07 D 401/04 C 07 D 471/04 C 07 D 471/08 C 07 D 487/08 C 07 D 519/00
X	GB-A-2 093 018 (KYORIN) * Page 1, lines 36-38; claim 8 * --	1-7,21	A 61 K 31/47 A 61 K 31/435 A 61 K 31/495
Y,D	EP-A-0 153 163 (WARNER-LAMBERT) * Page 3, line 16 - page 8, line 4; page 27, lines 8-12; page 79, lines 9-22; page 81, lines 1-14; page 82, lines 8-27 * --	1-21	C 07 D 215/00 C 07 D 401/00 C 07 D 471/00 C 07 D 487/00 C 07 D 519/00
Y	US-A-4 578 473 (J.M. DOMAGALA) * Column 1, line 49 - column 4, line 17 * --	1-7,21	A 61 K 31/00
Y	EP-A-0 004 279 (BAYER) * Page 16, line 4 - page 17, line 20; page 27, table 2, example 25 * & US-A-4 284 629 (Cat. D) --	1-21	C 07 D 215/00 C 07 D 401/00 C 07 D 471/00 C 07 D 487/00 C 07 D 519/00
X	US-A-3 221 015 (G. CIGNARELLA) * Claims 1,2 * --	28	A 61 K 31/00
X,D	EP-A-0 159 174 (WARNER-LAMBERT) * Page 7, line 1 - page 9, line 25; page 38; claim 1 * --	28	
The present search report has been drawn up for all claims ./. Place of search Date of completion of the search Examiner The Hague 28-11-1988 BRENNAN			
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			



European Patent  
Office

## CLAIMS INCURRING FEES

The present European patent application comprised at the time of filing more than ten claims.

- All claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for all claims.
- Only part of the claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims and for those claims for which claims fees have been paid, namely claims:
- No claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims.

## X LACK OF UNITY OF INVENTION

The Search Division considers that the present European patent application does not comply with the requirement of unity of invention and relates to several inventions or groups of inventions, namely:

1. Claims 1-27 excluding R' = 1-methylcyclobutyl,  
2-propenyl or  
1-adamantyl
2. Claims 1-6,21-26 as far as R' = 1-methylcyclobutyl
3. Claims 1-6,21-26 as far as R' = 2-propenyl
4. Claims 1-4,21-26 as far as R' = 1-adamantyl
5. Claim 28: Intermediate not being characterising part of first subject

- All further search fees have been paid within the fixed time limit. The present European search report has been drawn up for all claims.
- Only part of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the inventions in respect of which search fees have been paid, namely claims:
- None of the further search fees has been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the invention first mentioned in the claims, namely claims:

2025221730006



EUROPEAN SEARCH REPORT

Application number

EP 87 11 4686

- 2 -

DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.4)
A	<p>JOURNAL OF ORGANIC CHEMISTRY, vol. 31, no. 4, April 1966, pages 1059-1062</p> <p>P.S. PORTOGHESE et al.: "Bicyclic bases. Synthesis of 2,5-diazabicyclo(2.2.1)heptanes"</p> <p>* Abstract; page 1060, column 2, lines 8-12 *</p> <p>-----</p>	28	
The present search report has been drawn up for all claims			
Place of search	Date of completion of the search	Examiner	
CATEGORY OF CITED DOCUMENTS			
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document	T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document		



DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.4)
X	DE-A-3 509 546 (BAYER) * Claims 1-4; page 53, line 21 - Page 55, line 19; page 64, line 25 - page 68, line 29 * --	1-7,21	C 07 D 215/56 C 07 D 401/04 C 07 D 471/04 C 07 D 471/08 C 07 D 487/08 C 07 D 519/00 A 61 K 31/47 A 61 K 31/435 A 61 K 31/495
Y	EP-A-0 153 163 (WARNER-LAMBERT) * Page 3, line 16 - page 8, line 4; page 27, lines 8-12; page 79, lines 9-22; page 82, lines 8-27 * --	1-21	
Y	US-A-4 578 473 (J.M. DOMAGALA) * Column 1, line 49 - column 4, line 17 * --	1-7,21	
Y	EP-A-0 004 279 (BAYER) * Page 16, line 4 - page 17, line 20; page 27, table 2, example 25 * -----	1-21	
LACK OF UNITY OF INVENTION			
The Search Division considers that the present European patent application does not comply with the requirement of unity of invention and relates to several inventions or groups of inventions, namely:			
<ol style="list-style-type: none"> <li>1. Claims 1-27 excluding R' = 1-methylcyclobutyl, 2-propenyl and 1-adamantyl</li> <li>2. Claims 1-6, 21-26 as far as R' = 1-methylcyclobutyl</li> <li>3. Claims 1-6, 21-26 as far as R' = 2-propenyl</li> <li>4. Claims 1-4, 21-26 as far as R' = 1-adamantyl</li> <li>5. Claim 28: Intermediate not being characterising part of first subject.</li> </ol>			
The present partial European search report has been drawn up for those parts of the European patent application which relate to the invention first mentioned in the claims.			
Place of search	Date of completion of the search	Examiner	
The Hague	01-06-1988	BRENNAN	
CATEGORY OF CITED DOCUMENTS			
X : particularly relevant if taken alone	T : theory or principle underlying the invention		
Y : particularly relevant if combined with another document of the same category	E : earlier patent document, but published on, or after the filing date		
A : technological background	D : document cited in the application		
O : non-written disclosure	L : document cited for other reasons		
P : intermediate document	& : member of the same patent family, corresponding document		